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Abstract 
Human African Trypanosomiasis (HAT), also known as sleeping sickness, is a fatal chronic 
disease that is caused by flagellated protozoans, Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense. HAT is spread by a bite from an infected tsetse fly of the 
Glosina genus. Up to 60 million people in 36 countries in sub-Saharan Africa are at a risk of 
infection from HAT with up to 30 000 deaths reported every year. Current chemotherapy for 
HAT is insufficient since the available drugs exhibit unacceptable side effects (toxicity) and 
parasite resistance. Novel treatments and approaches for development of specific and more 
potent drugs for HAT are therefore required. 
One approach is to target vital proteins that are essential to the life cycle of the parasite. The 
main interest of this study is to explore Trypanosoma brucei cathepsin B-like protease (TbCatB) 
structural and functional properties with the primary goal of discovering non peptide small 
molecule inhibitors of TbCatB using bioinformatics approaches. TbCatB is a papain family C1 
cysteine protease which belongs to clan CA group and it has emerged as a potential HAT drug 
target. Papain family cysteine proteases of Clan CA group of Trypanosoma brucei (rhodesain 
and TbCatB) have demonstrated potential as chemotherapeutic targets using synthetic protease 
inhibitors like Z-Phe-Ala-CHN2 to kill the parasite in vitro and in vivo. TbCatB has been 
identified as the essential cysteine protease of T. brucei since mRNA silencing of TbCatB killed 
the parasite and resulted in a cure in mice infected with T. brucei while mRNA silencing of 
rhodesain only extended mice life. TbCatB is therefore a promising drug target against HAT and 
the discovery and development of compounds that can selectively inhibit TbCatB without 
posing any danger to the human host represent a great therapeutic solution for treatment of 
HAT.  
To understand protein-inhibitor interactions, useful information can be obtained from high 
resolution protease-inhibitor crystal structure complexes. This study aims to use bioinformatics 
approaches to carry out comparative sequence, structural and functional analysis of TbCatB 
protease and its homologs from T. congolense, T, cruzi, T. vivax and H. sapien as well as to 
identify non-peptide small molecule inhibitors of TbCatB cysteine proteases from natural 
compounds of South African origin. Sequences of TbCatB (PDB ID: 3HHI) homologs were 
retrieved by a BLAST search. Human cathepsin B (PDB ID: 3CBJ) was selected from a list of 
templates for homology modelling found by HHpred. MODELLER version 9.10 program was 
used to generate a hundred models for T. congolense, T, cruzi and T. vivax cathepsin B like 
proteases using 3HHI and 3CBJ as templates. The best models were chosen based on their low 
DOPE Z scores before validation using MetaMQAPII, ANOLEA, PROCHECK and QMEAN6. 
The DOPE Z scores and the RMSD (RMS) values of the calculated models indicate that the 
models are of acceptable energy (stability) and fold (conformation). Results from the different 
MQAPs indicate the models are of acceptable quality and they can be used for docking studies. 
High throughput screening of SANCDB using AutoDock Vina revealed nine compounds, 
SANC00 478, 479, 480, 481, 482, 488, 489, 490 and 491, having a strong affinity for 
Trypanosoma spp. cathepsin B proteases than HsCatB. SANC00488 has the strongest binding to 
Trypanosoma spp. cathepsin B proteases and the weakest binding to HsCatB protease.  
Molecular dynamics (MD) simulations show that the complexes between SANC00488 and 
TbCatB, TcCatB, TcrCatB and TvCatB are stable and do not come apart during simulation. The 
complex between this compound and HsCatB however is unstable and comes apart during 
simulation. Residues that are important for the stability of SANC00488-TbCatB complex are 
Gly328 of the S2 subsite, Phe208, and Ala256. In conclusion SANC00488 is a good candicate 
for development of a drug against HAT. 
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Chapter 1.   
1.1. Introduction 
Human African Trypanosomiasis (HAT), also known as sleeping sickness, is a fatal chronic 
disease that is caused by flagellated protozoans, Trypanosoma brucei gambiense (T. b. 
gambiense) and Trypanosoma brucei rhodesiense (T. b. rhodesiense) [1]. HAT is spread by a 
bite from an infected tsetse fly of the Glossina genus [2], [3]. An infection by T. b. gambiense 
causes a chronic disease that develops over months or even years before it reaches an advanced 
stage, where it affects the central nervous system while T. b. rhodesiense causes a form of the 
disease that can kill within weeks if not treated [4]. Another form of the disease which is found 
in Central and South America is American Trypanosomiasis or Chagas’ disease which is caused 
by the protozoa Trypanosoma cruzi (T. cruzi) [5], [3]. Chagas’ disease is the leading cause of 
heart disease in Latin America [6]. Other African trypanosomes are T. b. brucei, T. congolese 
and T. vivax, which are responsible for 'Nagana' disease in cattle and for causing huge economic 
damages every year with up to 46 million cattle threatened with Nagana in active foci [7].  
HAT occurs in 36 countries in sub-Saharan Africa. The form of the disease caused by T. b 
gambiense is found in west and eastern Africa while the T. b rhodesiense form is found in 
eastern and southern Africa [4]. The disease is found in rural areas where the tsetse fly can 
easily transmit the parasite between people and both domestic and wild animals. According to 
the World Health Organisation (WHO), close to 10 000 new cases of the disease were recorded 
in 2013. The actual number of infected individuals may be much higher since some people live 
in remote areas where the disease has not been monitored but it still poses a danger. Up to 60 
million people are estimated to be exposed to HAT in active foci but only up to 5 million live in 
areas where the disease is monitored [2] and it causes up to 30 000 deaths per year [8].  
Although, HAT is transmitted by a bite from an infected tsetse fly [2], [9], it can also be 
transmitted from mother to child during pregnancy as well as through the use of contaminated 
needles or by exposure to any other sharp objects [4]. The parasite infects the body in two 
stages; during the first stage (haemolymphatic phase), the parasite multiply in the blood, the 
lymph and the subcutaneous tissues [4]. Symptoms include headaches, fever and pains in the 
joints and itching [10]. During the second stage of the disease, the parasite infects the central 
nervous system by crossing the blood-brain barrier. During this phase of the disease, the 
infected person experiences changes in behaviour, confusion and poor coordination [10]. The 
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patient's normal sleep cycle is also disturbed, which gives the disease its name. This phase of the 
disease is also known as the neurological or meningoencephalic phase. If not treated, the 
infected person may die [4],[9].  
Diagnosis of HAT is carried out in three steps; (i) screening, (ii) diagnostic confirmation, and 
(iii) staging [4]. The Card Agglutination Test for Trypanosomiasis (CATT/T. b. gambiense) is 
used for screening [4], [10]. Other methods used are the cervical lymph node (CLN), palpain 
and puncture method [2], [4]. Diagnostic confirmation relies on screening results. Disease 
staging is carried out to determine the stage of the disease in the patient. In order to obtain direct 
evidence that the infection is from a trypanosome, blood, lymph node aspirate, or cerebrospinal 
fluid samples can be examined under a microscope. 
A variety of drugs are available for the treatment of HAT and they are administered according to 
the stage of the disease. Drugs used during treatment of the first stage of the disease are 
pentamidine and suramin [9], [10]. Both of these drugs are toxic and they have undesirable side 
effects on patients. The second stage of the disease is treated using melarsopropol and 
eflornithine [9], [10]. Treatment with melarsopropol has undesirable side effects like 
encephalopathy (brain dysfunction) [9], which can be fatal. There has also been an increase in 
resistance to the drug. Treatment with eflornithine is less toxic but difficult to administer and it 
is only effective against T. b. Gambiense [10]. Nifurtimox and benznidazole are used for the 
treatment of American Trypanosomiasis [10]. These drugs also have poor efficacy and they 
produce some serious side effects. These difficulties and dangers associated with administering 
currently available drugs make them inefficient and unattractive to use, therefore hampering the 
fight against the disease. This situation has motivated the search for new drugs that are more 
effective and more tolerable to administer without posing any danger to patients [11]. 
1.2. The biology and lifecycle of Trypanosoma brucei  
T. brucei is a unicellular parasitic protozoan belonging to the Trypanosoma genus in the 
Trypanosomatidae family and the order Kinetoplastida [2]. Kinetoplastids are unicellular 
flagellated eukaryotic protozoans that can exist as free-living microorganisms or as parasites of 
invertebrate, vertebrate and plant species [12]. Kinetoplastids that are pathogenic to human 
beings include T. b. gambience and T. b. rhodesience (cause HAT), T. cruzi (causes Chargas' 
disease) and Leishmania (causes Leishmaniasis) [10]. They are spindle shaped and have one 
mitochondrion flagellum which branches throughout the cell. The mitochondrion contains a 
specialized part called the kinetoplast, which contains the mitochondrion DNA (kDNA) of the 
organism. During the life cycle of the parasite, it goes through a trypomastigote form and an 
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amastigote form (in the mammalian host), and an epimastigote and a trypomastigote form (in the 
insect host) [2], [10]. The metacyclic trypomastigotes are injected into the mammalian host by 
the tsetse fly before it feeds on blood. The trypomastigotes first multiply at the site of the bite 
before they enter the bloodstream and the lymphatic system where they continue to replicate by 
binary fission. In the late-stage of the disease, the trypomastigotes enter the central nervous 
system (CNS) and occupy the cerebrospinal fluid and intercellular spaces. The trypomastigotes 
exist in two forms in the mammalian host: the long and proliferative bloodstream trypomastigote 
form which transforms into the short non proliferative intracellular amastigote. The amastigotes 
replicates within the cells before they transform back in to the infectious trypomastigotes and 
rupture the cell to release the trypomastigotes back into the bloodstream. In the gut of the tsetse 
fly the parasite exists as the replicative epimastigote and the infective metacyclic trypomastigote 
[2], [10],[9]. The trypomastigotes re-enter the tsetse fly when it feeds on blood containing the 
protozoan from an infected host. Figure 1.1 summarises the lifecycle of Trypanosoma brucei 
parasite as presented by the Centre for Disease Control and Prevention.  
1.3. Proteases  
Proteases (peptidases) are enzymes that catalyse the hydrolytic cleavage of peptide bonds [13] 
and they play an important part in vital biological processes in living organisms. Protease 
activity is dependent on their specificity, ability to access the scissile bond of the substrate, the 
activation of precursor enzymes and regulation of enzymes by endogenous protease inhibitors 
[14]. Proteases can be classified as exopeptidases (those that cleave at the end of a polypeptide) 
and endopeptidases (those that cleave within a polypeptide chain). Proteases that cleave 
polypeptide at the N-terminus are called aminopeptidases, and those that cleave at the C-
terminus are known as carboxypeptidases [15]. Some proteases, for example cathepsin B-like 
proteases, can perform both endopeptidase and exopeptidase activity [16]. 
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Figure 1.1: Diagrammatic representation of the lifecycle of T. brucei in humans (right) and the 
tsetse fly (left). T. brucei cathepsin B (TbCatB) which is essential for parasite survival is 
expressed in the bloodstream trypomastigote. 
 (http://www.cdc.gov/parasites/sleepingsickness/biology.html). 
Proteases can also be categorized into classes according to the basis of their mechanism of 
peptide hydrolysis. These include the five major protease classes; cysteine proteases (CPs), 
serine peptidases (SPs), metalloproteases (MPs), threonine and aspartic proteases [15]. Each 
class is characterised by a set of amino acid residues arranged in a particular configuration to 
form the active site [16]. These classes are sub divided in to clans and families according to 
protein sequence similarity at the active site. Any one of these proteases is expected to exist in 
multiple species as orthologous forms of one protease. Orthologous forms of a protease from 
different species are recognised by having the same biochemical specificity to substrates, they 
have the same optimum pH range and they show the same sensitivity to inhibitors. For this 
research, focus shall be on papain family C1 cysteine proteases which belong to Clan CA group 
since they are important during the lifecycle of T. brucei and to human health [12], [17],[18]. 
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Figure 1.2: Schematic diagram showing cysteine protease family and how cysteine proteases are 
related. Subfamilies are determined by sequence homology around the active site amino acid 
residues.  
1.3.1. Cysteine Proteases (Cps) 
Cysteine proteases (sometimes called thiol proteases), were first purified and characterized in 
1879 from Carica papaya, the papaya fruit [12]. CPs are found in all living organisms and they 
are comprised of six major families: the papain family, calpains, clostripains, streptococcal, viral 
and caspases/apopains [16]. The majority of discovered cysteine proteases are from viruses. 
Many are found in bacteria (e.g clostripain in clostridium) and fungi (cathepsin B in Aspergillus 
flavus). There are two main groups of cysteine proteases in mammals; cytosolic calpains 
(calpain type I, calpain type II) and lysosomal cathepsins (B, C, H, K, L, M, N, S, T, V, and W). 
There are ten clans recognised in the cysteine class (CA, CD, CE, CF, CH, CL, CM, CN, CO 
and C- a family not assigned to a particular clan). Classification of cysteine proteases into clans 
and families is based on sequence similarity, biochemical specificity to substrates and on 
possessing an inserted peptide loop as demonstrated in Figure 1.2 [12], [15]. 
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1.3.2. Structure and hydrolysis mechanism 
Cysteine proteases have a molecular mass of about 21-30kDa. They have an optimum pH of 4-
6.5 and they need to be in an environment which contains a reducing agent to avoid oxidation of 
the thiol group [19].  
Cysteine proteases like papain, cruzain, and cathepsin are mainly made up of antiparallel β 
sheets with segregated α and β protein subunits. The papain is the best characterized cysteine 
protease. The papain has 212 amino acid residues and its structure consist of two domains. The 
left hand (L-domain) consists of residues 10-108 and 207-212 while the right hand (R-domain) 
consists of the remaining residues [20], in accordance with the standard view. The L-domain 
consists of three α-helices. The central helix is the longest and it is oriented vertically. The R-
domain is mostly made of β-barrels with α-helix at the bottom.  The ‘V’ like shaped active site 
is located between the domains on top of the enzyme structure. The two catalytic residues Cys25 
and His159 (papain numbering), each from the N-terminal of the central helix of the L-domain 
and the β-barrel residues of the R-domain respectively, are located in the enzyme active centre. 
Figure 1.3 shows the crystal structure of papain in complex with the cysteine protease inhibitor 
E64 as adopted from PDB ID: 1PE6 [20]. The catalytic residues form the thiolate-imidazolium 
ion pair responsible for the proteolytic activity of all cysteine proteases and they are highly 
conserved in all cysteine proteases. These conserved regions can therefore be used to classify 
proteases and to clone orthologous genes. They can also be used to identify selective anti-
protease inhibitors and to predict natural compounds .The active site of papain like proteases is 
complemented with Asn175 to keep the His imidazole ring in optimal orientation during 
hydrolysis circles [21].  
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Figure 1.3: The crystal structure of the cysteine peptidase papain, PDB ID 1PE6 (green) in 
complex with its covalent inhibitor E-64 (orange). The Cys25 and His129 residues of the 
catalytic centre are located in the groove between the L and the R domains.  
The papain family cysteine proteases catalyse the hydrolysis of peptide, ester, thiol ester and 
thiono ester bonds [16]. The large binding site of papain allows for multiple interactions 
between the enzyme and the substrate which binds along the active site cleft in an extended 
conformation. These interactions are important during hydrolysis at the active site since they 
contribute to stabilization of intermediates that are formed. An essential cysteine residue is 
required in the active site for hydrolysis. During hydrolysis, the Cys25 residue is used as a 
nucleophile and the His residue is used as a general base [21]. The nucleophilic thiolate cysteine 
attacks the carbonyl carbon of the scissile bond of the bound substrate breaking the double bond 
between the carbon and oxygen to a single bond (Figure 1.3. A). This forms a tetrahedral 
intermediate which is stabilised by the oxyanion hole [16], [21]. Hydrogen bonding to the NH 
group of Gln19 side chain and Cys25 backbone stabilizes the oxyanion hole. The tetrahedral 
intermediate converts into an acyl enzyme (enzyme-substrate thiol ester) when protons are 
transferred from the imidazolium cation to the nitrogen of the peptide bond being hydrolysed, 
resulting in cleavage. Hydrogen bonds are formed between the His159 and the new substrate 
amide while the carboxylic part of the substrate is bonded to Cys25 by a thioester bond 
(acylation) (Figure 1.3. B). The amide part of the substrate dissociates and it is replaced by a 
water molecule. The polarized water molecule attacks the carbonyl carbon of the acyl enzyme, 
releasing the free enzyme and the N-terminal fragment of the substrate (deacylation) (Figure 1.3. 
C). The second tetrahedral intermediate is them formed. The last step involves the thioester 
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deacylation which results in the reconstruction of the carboxyl group of the hydrolysed peptide, 
at the same time readying the enzyme molecule for a new catalytic cycle (Figure 1.3. D). The 
hydrolysis mechanism of cysteine proteases as shown by the papain cysteine protease and as 
described by Rzychon et al is shown in Figure 1.3.  
 
Figure 1.4: The mechanism of hydrolysis of cysteine proteases as shown by papain (description 
is in text). 
The binding site of cysteine proteases has binding pockets called subsites. These subsites 
interact with substrate amino acids in the N-terminal and the C-terminal direction from the 
scissile bond. Subsites in the N-terminal (non-prime) direction are labelled S1, S2 and S3 and 
those in the C-terminal (prime) direction are named S1’, S2’ and S3’[8]. The substrates or 
inhibitor amino acids that bind in the subsites are named P1, P2, and P3 (those on the amino 
acid residue side of the scissile bond) and P1’, P2’, and P3’ (on the carboxyl-terminal side of the 
scissile bond) [15]. Active site residues are located in four loops located in both the L-domain 
(two short loops) and the R-domain (two large loops). The main interactions with the substrate 
are thought to occur at the S1, S3 and S2’ subsites of the L-domain loops and S2 and S1’ 
subsites of the R-domain loop in papain family cysteine proteases. It has been shown that the 
E64 inhibitor binds to papain by forming hydrogen bonds with residues of the S subsites and the 
catalytic sites [20]. All papain family proteases share similarities in hydrolysis mechanism, 
optimum pH range, molecular mass, enzyme activity and at the regions near the active site [16], 
[22].  
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1.4. Cysteine proteases of parasitic organisms 
1.4.1. Classification and evolution 
Cysteine proteases of parasitic organisms are divided into clan CA and clan CD proteases. 
Crucial parasite proteases are located in the papain family C1 cysteine proteases of clan CA 
group (Cathepsin-L and Cathepsin-B like) [23] and in the C2 family (calpain-like). Cysteine 
proteases of pathogenic organisms, specifically papain family C1 proteases belonging to clan 
CA group have been implicated in the virulence-associated with the organisms [17]. They 
contain the plant papain cysteine protease, and the mammalian lysosomal Cathepsins B, C, K, L 
and S. In human, C1 proteases Cathepsin-L and Cathepsin B proteases are important in the 
immune system for protein degradation/turnover (cathepsins B, L and H), and for bone 
resorption (cathepsin K). In parasites, they are important for host entry, feeding and suppression 
of the host immune responses, for example brucipain is involved in parasite migration across a 
model of the blood-brain barrier [18]. Papain- family C1 proteases of Clan CA, are crucial for 
parasitic diseases and many of them have been identified as promising drug targets, like 
falcipain-2 of P.falciparum. Other cysteine protease of Trypanosomes are papain-like family 
C13 belonging to Clan CA (GPI:protein transamidase) and C50 (separase) of clan CD. Other 
clans and families of parasitic organisms include clan CB and CC (viruses) and legumain-like 
family C13 proteases belonging to Clan CD. Cysteine proteases of parasitic organisms are 
products of independent evolutionary events. This is demonstrated by the order of catalytic 
residues Cys/His (as in clan CA) or His/Cys (as in clan CD) in their protein sequences [12] . 
1.4.2. Papain-like family proteases 
The papain like family C1 cysteine proteases of Clan CA makes the majority of parasitic 
cysteine proteases [24]. Their catalytic activities includes endopeptidases (papain and glycyl), 
and aminopeptidases (Cat H). They also include peptidases with both endopeptidase and 
exopeptidase activity like Cathepsin B and H [16]. A common feature of all papain-like cysteine 
proteases is that they are made up of a peptide, a propeptide (prodomain) and a catalytic domain. 
The catalytic domain represent the mature active enzyme [15]. The function of the 10-20 amino 
acid long peptides is translocation into the endoplasmic reticulum during ribosomal protein 
expression. The prodomain is responsible for protein folding of the catalytic domain. The 
prodomain also plays a role in the transport of the proenzyme to the endosomal-lysosomal 
compartment. Thirdly it acts as a high-affinity reversible inhibitor to prevent the catalytic 
domain from being activated prematurely. The catalytic domain of papain-like proteases is 220-
260 amino acids long [15]. An exception is made for cysteine proteases from some parasites 
whose cysteine proteases contain a C-terminal extension of unknown function. The catalytic 
10 
domain of papain like proteases has the most highly conserved regions when compared to the 
other two domains. As mentioned previously, the conserved active site of cysteine proteases 
consist of a cysteine, histidine and asparagine residues. Another feature of clan CA proteases is 
that they are inhibited by E64 (L-trans-epoxysucciny-leucyl-amido (4-guanidino) butane) and 
that their substrate specificity is define by the S2 pocket [12], and their specificity is restricted to 
members of the chathepsin sub families.  
1.4.3. Lysosomal cysteine proteases 
Lysosomal cysteine proteases, also known as cysteine cathepsins (Cats) are crucial in many 
biological processes in all living organisms as they are involved in degradation of extracellular 
and intracellular material [22], [25]. Cysteine cathepsins have pH-optima of 5.0 – 6.5, but they 
can be stable at different pH conditions, for example cathepsin S which is stable and active at a 
neutral and a slightly alkaline pH. Human cysteine cathepsins include cathepsins B, C, F, H, K, 
O, L, S, V, X, and W [12], [14], [22]. Cathepsins share the same amino acid sequences and 
mechanism of action as other members of the papain family. They however display a broad and 
distinct substrate specificity and regulation, preferring to cleave the substrate after basic or 
hydrophobic residues [16]. Cysteine cathepsins are mostly endopeptidases (except Cat C) and 
they can work as both endopeptisase and exopeptidase enzymes (Cat B) and as aminopeptidases 
(Cat H). They are glycosylated and phosphorylated in the golgi apparatus as precursor proteins. 
The majority of  chathepsins are monomeric proteins of Mr ~ 30-50 kDa, an exception is made 
for Cat C which is an oligomeric enzyme of Mr ~ 200kDa [14].  Most of them are ubiquitously 
expressed (B, H, L, C, F, O and V) and they are involved in normal protein degradation and turn 
over. The most abundant of these is cathepsin B which has been implicated with cancer and is 
capable of degrading extra-lysosomal matrix in diseases such as muscular dystrophy, and 
rheumatoid arthritis [25]–[27].  Other cathepsins, (K, W, S) are expressed only in specific 
tissues or cells which indicates a more specific role. Cathepsin S is restricted to the major 
histocompatibility complex in antigen presenting cells (APCs) derived from the bone marrow. 
Cathepsin K, which plays a role in bone resorption, is mainly expressed in the osteoclasts, in 
epithelial cells and in the synovial fibroblasts in rheumatoid arthritis joints. Cathepsin W is 
expressed in the CD8+ T-lymphocytes and in natural killer cells. Other tissue-specific 
cathepsins are Cat V which is expressed in the thymus, testis and cornea [14], [22]. 
The expression of lysosomal proteases is regulated in order to allow the cell to respond to 
changing physiological situations. An imbalance in their enzymatic activity has been found to be 
involved in pathological conditions. The involvement of cathepsins in diseases seems to be 
restricted to their enzymatic activity outside the lysosome as a result of an imbalance between 
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their catalytic activity and their natural inhibitors. Cysteine cathepsins are associated with 
arthritis, neurodegenerative as well as cardiovascular diseases. Genetic diseases like severe bone 
abnormalities (pycnodysostosis) is linked to a mutation that results in a loss of function of Cat 
K, while a loss of function mutation of Cat C gene is linked to Papillon-Lefevre syndrome [14]. 
1.5. The role of cysteine proteases in Trypanosomes 
Trypanosomes contain cysteine proteases that are regulated at different stages during their life 
cycle. Through gene manipulation and the use of specific inhibitors, studies have revealed the 
role of enzymes in parasite pathogenicity, in manipulation of the host immune system and in 
parasite replication [28]. The enzymes with the highest activity in trypanosomes are Type I 
cysteine proteases. Type I cysteine proteases of trypanosomes have a distinct carboxy-terminal 
extension that sets them apart from other cysteine proteases. The mRNA of TbCatB is mostly 
expressed in the blood stream form of the parasite [29]. Cruzipain and gp57/51, cysteine 
proteases from Trypanosoma cruzi are expressed throughout the life cycle of the parasite. They 
are most abundant in the replicating forms and in the epimastigote stage in the insect host. 
Previous analysis of trypanosomes has shown that Type I cysteine proteases are encoded by 
multicopy genes arranged in tanden arrays. During the development of the parasite, proteases 
are synthesized to serve different functions. 
1.5.1. Nutrition 
Cysteine proteases have evolved to hydrolyse proteins early on in their evolution. This is 
confirmed by their existence in parasites and other cellular organisms that represent the earliest 
forms of eukaryotic cells. They are capable of carrying both endogenous and exogenous protein 
degradation. Their exogenous activity is best exemplified by the hydrolysis of haemoglobin by 
cathepsin-B1 (SmCBI) of S. mansoni and falcipain 2 of P. falciparum (Fp2) [12]. The blood 
stream form of Trypanosoma brucei lacks cytochromes, so they acquire iron from the host by 
degradation of transferrin using TbCatB in the lysosomes [29].  
1.5.2. Tissue and cell invasion 
Cysteine proteases are involved in cellular process and they are thought to play a role in cell 
invasion in T.cruzi. According Sajid & McKerrow, parasite invasion and development were 
reported to be reduced by peptidyl diazomethane inhibitors in vitro. Brucipain is thought to 
facilitate in disruption of the blood-brain barrier [18]. 
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1.5.3. Encystment and hatching 
An infection by a parasite is usually followed by the formation of a cyst where the insect (tsetse 
fly) bit the host and deposited the parasite. The parasites first multiply in this protective cyst 
before they hatch and invade other parts of the host. Proteases are required during the formation 
of a cyst and during the cyst rupture for infection to occur [12]. 
1.5.4. Immunoevasion 
During invasion of the host cells, parasites need to find a way to evade the host immune system. 
It is hypothesized that parasites cysteine proteases are involved in evading the immune system 
of the host. African trypanosomes seem to release Cysteine proteases into the host bloodstream, 
and these released enzymes are suspected of causing platelet aggregation thereby contributing to 
the pathogenicity of the disease  [28]. Cysteine protease inhibitors of T. cruzi have been 
documented hydrolysing the host antibodies [12]. Cruzain, the major cysteine protease of T. 
cruzi, has been connected to blood plasma leakage in veins. Cruzain is also suspected of 
recruiting macrophages for invasion of host cells. Cathepsin-L like proteases have been linked 
to the reduction of secretory leukocyte protease inhibitor, (a protective inhibitor found in saliva, 
blood, tears and vaginal fluid). 
1.5.5. Non Erythrocytic parasite stages 
There is limited data on the role of cysteine proteases in the non erythrocytic parasite stages. 
Allergic responses have been reported for T. cruzi and papain active enzyme in mice. 
1.6. Cysteine protease inhibitors mechanism 
Cysteine proteases produced by parasitic organisms play a role in the pathogenicity of the 
organisms and their effect in the host may lead to an imbalance in endogenous protease activity, 
which in turn may lead to formation of diseases. Precise regulation of protease activity is 
essential for homeostatic cell activity and organism survival. Biological systems have developed 
natural ways (regulated expression, secretion and activation of the pro-proteases) to protect the 
organism from unwanted protease activity [30]. Protease inhibition is one way of regulating 
protease activity and contribution to protection against exogenous protease activity. An 
understanding of the inhibitory mechanisms employed by natural protease inhibitors may 
provide prospects into application of selective inhibitors in chemotherapy. Cysteine protease 
inhibitors act by blocking access to the active centre from the substrate. Natural inhibitors have 
developed effective mechanisms to archive this [21]. 
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1.6.1. The propeptide backward binding mechanism  
Cysteine proteases are synthesized as inactive precursors [26], activation of newly synthesized 
cysteine protease precursors requires proteolytic cleavage of the N-terminal prodomain that 
inhibits the mature enzyme [8]. The mechanism of propeptide inhibition was revealed by 
crystallographic studies of procathepsins B, L and K. Most cysteine protease prodomains are 
made up of two domains; the N-terminal domain which is made up of two α-helices and an 
extended β-strand and the C-terminal domain which interacts with the “proregion binding loop” 
of the mature protease. During inhibition, the C-terminal segment blocks the substrate binding 
site using its backbone and cuts access to the enzyme active site by binding between the two 
domains that make up the enzyme [8], [21]. The proenzyme covers most of  most of the 
enzyme’s hydrophobic surface behind the S1’ subsite by exposing its own hydrophilic surface to 
the solvent [26]. 
1.6.2. The pSpeB mechanism (profragment that distorts the enzyme catalytic centre) 
Streptococcal pyrogenic exotoxin B (SpeB) is a papain like protease isolated from Streptococcus 
pyogenesis [31]. Its profragment is made up of four-stranded antiparallel β-sheet flanked by α-
helices. To archive inhibition of the SpeB enzyme, the catalytic His195 residue is pushed out 
from the active centre, so that it does not interact with the catalytic Cys47 residue. This is 
accomplished when the Asn89 residue penetrates the substrate binding site of the mature 
enzyme in a position similar to the S1’ site in papain-like proteases [21]. 
1.6.3. The serpins mechanism (covalent interaction and catalytic centre distortion) 
According to Rzychon et al. 2004, some serine protease inhibitors can block both serine and 
cysteine protease activity. These serpins are distinguished by a surface exposed reactive site 
loop that is a target for proteases. Serpins inhibit an enzyme by partial denaturing and disruption 
of its catalytic centre [32].  
1.6.4. The p35 mechanism (covalent inhibition and steric hindrance) 
The p35 is a virus cysteine protease covalent inhibitor which is produced to suppress the host 
immune response by forming a thioester bond with caspases [33]. The p35 protease inhibitors 
can inhibit almost all caspases but have no activity towards other protease families. The p35 
inhibitor blocks access to the caspace catalytic His317 residue to inactivate the enzyme [33], 
[21]. 
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1.6.5. The cystatins mechanism 
Cystatins are the largest and most well described natural inhibitors of cysteine proteases. 
Cystatins inhibit the activity of papain superfamily members in viruses, bacteria, plants and 
animals. They are divided in to stefins (family I), cystatins (family II) and kininogens (family 
III) according to sequence homology. They block access of the substrate by binding adjacent to 
the protease active site without directly interacting with the catalytic centre. Cystatin inhibitory 
domain is made up of five-stranded antiparallel β-pleaded sheets surrounding α-helix. The 
domain forms a chisel like shape that fits in the papain active site. The N-terminus is 
distinguished by Gly8 and Ala10 residues and two hairpin loops carrying conservative motifs 
QVVAG and PW. During inhibition, the two hairpin loops interact with the protease surface 
from S1’ to the S4’ binding sites while the N-terminal of the cystatin interacts with the S3-S1 
subsites. This leaves the polypeptide chain pointing away from the enzyme active site at the P1 
position, avoiding cleavage [21], [30]. 
1.6.6. The thyropins and chagasins mechanism 
Thyropins mechanism of inhibition has been described as efficient as and more selective (to 
cathepsin L) than that of cystatins owing to its structure which allows extra contact with 
protease surfaces [34]. Chagasins were first identified in Trypanosoma cruzi and they inhibit 
papain like proteases. Their inhibition mechanism is comparable to that of cystatins [21]. 
1.6.7. The IAP mechanism 
Inhibitors of the apoptosis protein family (IAP) are endogenous cysteine protease inhibitors that 
directly inhibit caspases. They have a characteristic subunit structure with one or more BIR 
(baculovirul IAP repeat) domain. Their mode of inhibition works by sterically blocking the 
substrate access to the enzyme catalytic centre [21], [35]. 
1.6.8. Staphostatins 
Staphostatins are highly specific towards bacterial papain-like cysteine proteases called 
staphopains. They are able to inhibit protease activity my preventing the stabilisation of the 
tetrahedral intermediate during proteolysis [21]. 
Mammalian homologs of parasite proteases are currently being targeted by pharmaceutical 
companies and this has produced a group of inhibitors that are suitable drug targets against 
parasitic diseases. However, for these inhibitors to be useful for clinical purposes, they have to 
be selective for parasite proteases only and not affect parasite protease homologs in human. 
Several compounds that can target parasite proteases without posing danger to the host have 
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been demonstrated; Vinyl sulfone-derivatised pseudopeptides have been shown to cure mice 
infections of T. cruzi [12]. This indicates that cysteine proteases inhibitors can be developed to 
make effective, safe and orally administered drugs against parasitic diseases.  
1.7. Trypanosoma brucei Cathepsin B like proteases (TbCatB) 
TbCatB is a papain family C1 cysteine protease which belongs to Clan CA group. It is secreted 
together with another cysteine protease, rhodesain, a cathepsin L-like protease which was 
previously thought to be the essential cysteine protease of the parasite [23]. Research has shown 
that RNA interference of rhodesain did not eliminate the parasite from cell cultures while RNA 
interference of TbCatB killed cultured parasite [18], and cured infected mice [29]. So, TbCatB is 
a more promising drug target than rhodesain. 
1.7.1. Expression by parasites 
In the mammalian host TbCatB and rhodesain are both produced by bloodstream T. brucei 
although it is produced in smaller amounts [23]. During the lifecycle of the parasite, the mRNA 
of TbCatB is expressed in larger quantities in the metacyclic trypomastigote (bloodstream) stage 
than in the procyclic trypomastigote (tsetse fly) stage [29] 
1.7.2. Biochemical characterisation 
Sequence analysis of TbCatB has shown it to be a 341 amino acid polypeptide with a predicted 
Mr of 37.223. Its open reading frame is made up of the same motifs identified in the active sites 
of lysosomal cathepsins. TbCatB is a carboxypeptidase of both endopeptidase and exopeptidase 
activity. In common with all the other Clan CA cysteine proteases, the catalytic triad, 
Cys122(29), His282(199), and Asn302(219) (TbCatB numbering with HsCatB numbering in 
brackets) is present. The open reading frame of TbCatB also encodes Gly-Cys-Xaa-Gly-Gly 
motifs, which are found in cathepsin B family proteases. In human cathepsin B (HsCatB), this 
motif is similar to residues 70-74. In addition to all the features common to Clan CA cysteine 
proteases, the cathepsin B-like enzyme has an ‘occluding loop’. The occluding loop of TbCatB 
contains histidine residues (His194 and His195) which are used to dock the C-terminal 
carboxylic group of peptidyl substrates [29]. A unique feature of cathepsin B proteases is the 
presence of Glu245 residue as part of the S2 subsite [22] while TbCatB contanins Gly328 at the 
same position [23]. 
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1.7.3. Structure and function of TbCatB domains 
The crystal structure of TbCatB in complex with CA074 has been reported at a refined 
resolution of 1.60 Å and having an R-free of 17.8 % and an R-factor of 14.7 % [23]. TbCatB 
shares the papain like fold that is characteristic of cathepsin B-like proteases [8], [36]. Its 
structure is made up of the L-domain and the R-domain. The L-domain consists of three α-
helices with the central helix arranged vertically while the R-domain is made up of six 
antiparallel strands that form a twisted β-pleated sheet with α-helix at the bottom and a helical 
loop segment on top. It also has an ‘occluding loop’ which is a unique characteristic of cathepsin 
B-like proteases. The occluding loop covers the prime side of the substrate binding site and it is 
thought to give cathepsin B-like proteases their exopeptidase activity [29] by the removal of 
dipeptide units from the C-terminus end of the substrate [37]. The occluding loop of TbCatB has 
a rigid and a flexible (mobile) region. As observed in HsCatB, the occluding loop in TbCatB can 
be oriented in a “closed” conformation which results in the flexible region covering the S1’ and 
S2’ subsites at the substrate cleft or “open” conformation which exposes the hydrophobic 
subsites. The S1’ and S2’ subsites are highly conserved between human and trypanosome 
cathepsin B proteases. The occluding loop in TbCatB is found to be more rigid than that of 
HsCatB. This results from the differences in the number of hydrogen bonds in the flexible part 
of the occluding loop. When the occluding loop of TbCatB is in the closed conformation, four 
hydrogen bonds from residues (His189, His190, His194 and His195) restricts the flexible part of 
the loop to four residues which results in an opening of 8.5Å in the occluding loop crevice. In 
HsCatB, one hydrogen bond is involved in the closed conformation, the flexible part of the loop 
then has ten residues which results in an opening of 11.9Å in the crevice [8]. The occluding loop 
in TbCatB has three residues (Lys197, Try202 and Phe208) that are not available in mammalian 
homologs and it has a different motif (“FNFD”) to that of mammalian cathepsin B (“GEGB”). 
The two phenylalanine residues in the “FNFD” motif of TbCatB results in a more stable opening 
around the S1’ subsite while glycine residues in the “GEGD” motif in HsCatB results in the 
flexibility that allows movement of the Glu residue in and out of the S1’ subsite. The mature 
domain of TbCatB is also reported to have a longer N-terminus when compared to that from 
rhodesain, HsCatB and papain. It shares this feature with malarial proteases falcipain-2 (FP-2) 
and falcipain-3(FP-3)[23]. The structure of TbCatB is shown in Figure 1.3. 
1.7.4. Structural basis of TbCatB inhibition 
The specificity of a protease results from interactions between the substrate and the enzyme 
substrates at the active site [22]. Understanding these interactions and how they differ between 
HsCatB and TbCatB can aid in the design of parasite specific inhibitors. According to Turk et 
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al, only three substrates binding sites (S2, S1 and S1’), are well defined for substrate residues to 
interact with the enzyme by main and side chain interactions while the S3 and the S4 binding 
sites are not real sites but areas in which the substrate residues find their most favourable 
binding position. Vertebrate cathepsin B proteases were described as having an acidic residue at 
the bottom of the S2 subsite to assist in binding with basic P2 residues. The S2 of TbCatB has a 
Gly328 in this position while that of HsCatB has Glu245. The small TbCatB Gly residue allows 
for a large and deep S2 pocket which can accommodate lager P2 residues whereas the large Glu 
residue results in a smaller and shallower S2 pocket in HsCatB [23]. Acidic residues (Asp166, 
Asp168, Asp258) line the sides while Asp327 lines the bottom of the S2 subsite making TbCatB 
acidic in this position [23]. The occluding loop of TbCatB contains His194 and His195 residues 
which are used to dock the C-terminal (carboxylic group) of peptityl substate during hydrolysis. 
Another difference between the occluding loop of TbCatB and the HsCatB protease is the 
possession of “FNFD”motiff by TbCatB, which corresponds to “GEGB” in HsCatB. Differences 
between the HsCatB protease and the TbCatB protease could be exploited to design additional 
specificity to parasite specific inhibitors [8]. 
 
 
Figure 1.5: Cartoon plot of the TbCatB protease (PDB ID 3HHI) showing the typical papain-like 
fold of cathepsin B-like proteases. The L domain (Navy Blue), R domain (grey) and the 
occluding loop (orange) are highlighted. The active site residues (Cys122, His282 and Asn302) 
are high highlighted yellow, green and red respectively. Occluding loop His194 and His195 
residues are shown as pink sticks. The Gly328 residue of the S2 subsite is shown in magenta. 
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1.7.5. Peptide based inhibitors of TbCatB 
Peptide based inhibitors of proteases are characterised by a peptide segment in order to be 
recognized by enzymes. This peptide segment is an electrophilic moiety (warhead), which can 
undergo nucleophilic attack of the cysteine residue of the active site. They usually inactivate the 
enzyme irreversibly. To avoid reactivity of inhibitors with non-target host proteases, focus has 
been on developing papain like selective inhibitors that can identify parasite proteases from 
mammalian proteases by taking advantage of the amino acid residues around the cleavage site in 
the catalytic pocket. Electrophilic moieties that can be used as warheads incudes aldehydes and 
ketone derivatives, examples include chloromethyl, fluoromethyl, and diazomethyl ketones. 
Methyl ketone derivatives tested against T.b. brucei cultures have shown they can inhibit 
cysteine proteases. Another class of cysteine protease peptidic inhibitors contain the vinyl 
sulfone moiety which forms covalent bonds with the active Cysteine residue [38]. 
1.7.6. Non peptide inhibitors 
Non peptidyl TbCatB inhibitors belonging to different classes of chemicals including 
acylhydrazides, ureas and thioureas, thiosemicarbazones and triazine nitriles have been 
identified by virtual or high throughput screening followed by rational drug design by molecular 
modelling studies [38]. A series of purine derived nitriles that display selectivity against TbCatB 
have been developed using homology modelling methods [39].  
1.7.7. Peptidomimetic TbCatB inhibitors 
Peptide based inhibitors have limitations when it comes to their clinical application. They can be 
degraded by endogenous proteases and they have low selectivity. Another limitation of peptide 
based inhibitors is that their absorption through the cell membrane and the blood brain barrier is 
poor. Peptidomimetic drug design has therefore become attractive in improving pharmacokinetic 
and pharmacodynamics drug properties. Research has been carried out on the development of 
peptidomimetic cysteine protease inhibitors based on the 1, 4 benzodiazepine scaffold as a β-
turn mimetic. The β-turn is proposed as the structural motif for biologically active linear 
peptides. The benzodiazepine (BZD) nucleus is an excellent mimetic of the β-turn types, and it 
has both oral bioavailability and tolerability as attested to its use in medication (as muscle 
relaxants, anxiolytics, hypnotics and anticonvulsants) [38].  Reported effective inhibitors are 
aldehydes, α-halomethyl ketone, nitriles, epoxides, aziridines, and Michael-type acceptors. 
Vinyl sulfones with added functional groups that can react with the protease sulfur atom have 
also been reported as cysteine protease inhibitors [40].  
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1.7.8. Inhibition by endogenous macromolecules 
Cysteine proteases are synthesized as inactive protease precursors. The N-terminal propeptide 
function as a selective inhibitor until the enzyme reaches the lysosome. In the lysosome, the 
propeptide is released and the mature active enzyme is formed. This mode of inhibition can be 
used to develop inhibitors that are species specific, but structural information on protease and 
inhibitor interaction is needed. More information is also needed to understand the extent of 
structural conservation between the mammalian and the trypanosome cathepsin B active site [8]. 
1.8. Problem statement and research justification 
HAT is an example of a neglected disease and this has affected the development of new 
diagnostic tests and drugs [2]. Currently available drugs were developed based on their non-
parasite properties without knowledge of the biochemical pathways of the parasite and therefore 
they are accompanied by lack of specificity to the target organism, poor efficacy and high levels 
of toxicity [40], [8]. Due to undesirable side effects, and the dangers associated with 
administering currently available drugs against HAT, it is necessary to develop new and more 
effective drugs against the parasites that cause the disease. Another reason to develop new drugs 
is because the parasites are growing resistance to some of the available drugs.  
The process of drug discovery historically involved high throughput screening (HTS) of 
compounds in order to identify hits or biologically active compounds. This process is not only 
labour intensive and expensive, it also does not always end with the identification of a potent 
compound. To enhance this process, and potentially reduce time and cost, in silico methods like 
structure based drug design provide an alternative approach. These methods use information 
from high resolution 3D protein structures to explore the connection between structure and 
function, identify and select drug targets, study residues that are involved in protein-ligand 
interactions and characterize the binding pockets, develop a library of compounds that are 
specific for the targets, identify hits by docking experiments, and then make an optimisation of 
the lead compounds  [41]. The in silico approach has gained significant attention in drug 
development for the treatment of parasitic diseases in the development of compounds that 
selectively inhibit proteases (enzymes) that are crucial for the survival of the parasites. These 
enzymes should be significantly different within the mammalian host to avoid accidental 
targeting of host proteases [38], [42]. Parasite proteases present a good target because they play 
an important role in replication, metabolism, survival and pathology of the organism [40].  
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Genome sequencing projects have shown that proteases make up approximately 2% of all 
expressed genes and their sequences does not differ a lot between organisms [12]. The main 
catalytic protease groups are serine, threonine, aspartate, metallo and cysteine proteases. The 
cysteine (thiol or sulfhydryl) proteases have gained interest as drug targets against parasitic 
diseases since they have been recognised to be critical to the life cycle or virulence of many 
parasites. Cysteine proteases of parasites are important in pathogenicity, tissue and cellular 
invasion, immunoevasion, enzyme activation, excystment, hatching and moulting. Papain family 
C1 cysteine proteases which belong to Clan CA group are important for metabolic pathways 
during the life cycle of parasitic organism so they present a valuable drug target for the 
treatment of parasitic diseases [23] and many of them have been identified as promising drug 
targets, like falcipain-2 of P.falciprum. Targeting of essential enzymes has also been employed 
in mycobacterium tuberculosis research in which peptidoglycan biosynthesis was a targets for 
drug development [43]. Parasites rely on essential cysteine proteases for survival; e.g cruzipain 
is an essential cysteine protease for T. cruzi and TbCatB and rhodesain are essential cysteine 
proteases for T. brucei [44]. Inhibition of the activity of essential cysteine proteases has been 
shown to be lethal to parasites, for example the cysteine protease of T. brucei is a validated drug 
target [29]. This was demonstrated by the in vitro and in vivo killing of the parasite with the 
cysteine protease inhibitor benzyloxycarbonyl-phenylalanine-alanine- diazomethane (Z-Phe-
Ala-CH2). Although both rhodesain and TbCatB have been identified as essential cysteine 
proteases for T. brucei mRNA interference of TbCatB was demonstrated to cure mice from a 
lethal dose of T. brucei while interference of rhodesain only extended mouse life [23]. This 
therefore marks TbCatB as a better candidate than rhodesain as a drug target for treatment of 
HAT. The discovery and development of compounds that can selectively inhibit TbCatB 
without posing any danger to the human host represent a great therapeutic solution for treatment 
of HAT. An understanding of cysteine protease properties is important towards the development 
of inhibitors for pharmaceutical and agricultural applications.  
To design potent and selective inhibitors, it is necessary to know the high-resolution structure of 
a target protease. Useful information about the binding interactions of inhibitors with protease 
structures can be obtained from crystal structure complexes with inhibitors [5]. Experimental 
methods like X-ray crystallography and nuclear magnetic resonance (NMR) can be used to 
determine high resolution crystal structures [45]. However, difficulties associated with 
purification and crystallization of 3D protein structures has slowed down the determination of 
high resolution crystal structures by X-ray crystallography and NMR techniques [41]. Crystal 
structure determination (x-ray and NMR) of proteases is far behind sequence determination [16] 
and so only a few crystal structures of selected proteins can be found in the Protein Data Bank.  
21 
 
In the absence of an experimentally determined crystal structure, when the amino acid sequence 
of a protein is known, homology modelling methods can be used to predict a reliable three-
dimensional model of that protein by using coordinates of proteins with a known structure that 
share 30% or more sequence identity with the protein of interest [46]. Bioinformatics 
approaches like homology modelling for protein inhibitor docking provide a solution for solving 
and understanding protein interactions [43], [47]. The general principle used in homology 
modelling is that when given a homologous protein with known crystal structure, the crystal 
structure can be used as a template to model the 3D structure of the protein of interest [48]. The 
availability of the crystal structure of TbCatB (PDB ID: 3HHI) in complex with CA074 makes it 
possible to use bioinformatics approaches to carry out comparative sequence, structural and 
functional analysis of TbCatB protease and homologs. 
The focus of this study is to explore the properties TbCatB protease and homologs, with the 
primary goal of identifying nonpeptidic small molecule inhibitors of TbCatB using 
bioinformatics tools. 
1.8.1. Hypothesis 
The project hypothesis is that the active site of TbCatB protease is different from that of HsCatB 
protease and so TbCatB protease can be used as a drug target against HAT. 
1.8.2. Aims 
The aim of this project is to use bioinformatics approaches to perform comparative sequence, 
structural and functional analysis of TbCatB cysteine protease and its homologs. 
The project also aims to use molecular docking experiments and the South African natural 
compound database (SANCDB)[49] to screen for small molecule inhibitors (hits) of cathepsin B 
proteases and identify natural compounds that can lead to development of a drug against HAT.  
1.8.3. Objectives 
To use BLASTP to search and retrieve TbCatB protease sequence homologs from T, cruzi, T. b. 
brucei, T. vivax, T. congolese and to use HHpred to retrieve the HsCatB protease template for 
homology modelling. 
To carry out multiple sequence alignment of TbCatB and its homologs to determine residue 
characteristics whose effect on the substrate will be analysed by docking experiments. 
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To carry out phylogenetic analysis of aligned protein sequences in order to determine their 
evolutionary relationship. 
To build homology models of protein tertiary structures to determine structural properties of 
TbCatB and its homologs. 
To perform inhibitor docking experiments on the protein model structures of TbCatB and 
homologs using natural compounds of South African origin to determine inhibitor and protein 
interaction characteristics. 
 Identify small molecule TbCatB inhibitors (hits) that can lead to development of a drug against 
HAT from the South African Natural Compounds Database (SANCDB).  
To carry out molecular dynamics of the selected lead compounds to determine the stability of 
the ligand-protein complex models. 
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Chapter 2.   
 
Homology Modelling and Protein Structure Analysis 
In this chapter, bioinformatics approaches and databases shall be used for sequence, structural 
and functional analysis of TbCatB protease and its homologs. The sequences shall be identified 
from sequence and structural databases and then analysed using sequence and structural 
approaches. Protein function and structure is encoded in sequences [50],[51] it is therefore 
important to get information about the 3D structure of a protein in order to understand how it 
performs its function [45]. Due to difficulties associated with experimental determination of 3D 
protein structure [41], only a few 3D crystal structures of cathepsin B protease are available. 
Available cathepsin B-like protease crystals structures that are relevant to this project are those 
from T. brucei, T. b. brucei, and H. sapiens. The availability of these structures makes it 
possible to calculate 3D models of homologous proteases using bioinformatics methods such as 
homology modelling. As mentioned in chapter 1, HAT is caused by the protozoan parasite 
Trypanosoma brucei which is spread by tsetse flies [8]. Another form of the disease is Chagas’ 
disease which is caused by T.b. cruzi [5]. Other trypanosomes include those that cause nagana 
disease in livestock. These are T.b.brucei, T. congolense and T. vivax [7]. Homology models 
shall be calculated for cathepsin B-like proteases from H.sapien, T. cruzi, T. congolense and T. 
vivax. Comparative structural analysis shall then be carried out to identify residues that are 
involved in protein and ligand interactions at the active site. 
Once the sequence of interest also known as the target sequence is identified, four major steps 
are usually followed in homology modelling. The first step is to identify the template from 
which it will be calculated. A template and target sequence alignment is then made to assign 
residue correspondence before a model is calculated. If necessary the model is refined and then 
validated before it can be used for further application [50], [41]. In this project, the validated 
models shall be used for protease-inhibitor docking studies of natural compounds of South 
African origin. Compounds that inhibit TbCatB protease more than they do the human homolog 
shall be identified as leads compounds that can be used for development of drugs for HAT. 
Homology modelling and docking studies have been used by other researchers to screen for 
inhibitors with therapeutic applications [43], [45]. 
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2.1. Introduction 
Methods for predicting the 3D structure of a protein from sequence information includes; (i) ab-
initio methods which are based on physical chemical principles, (ii) homology methods that are 
reliant on information available in sequence and structural databases and (iii) threading of fold 
recognition methods which rely on finding a template structure that closely resembles the 
structure of the query sequence [52]. Genome projects are producing sequences faster than X-
ray crystallography and NMR laboratories can solve 3D-structures [41]. The rapid expansion in 
sequence databases, coupled with new sequence and structure analysis algorithms have increase 
the accuracy of homology models, making homology modelling a method of choice for 
predicting 3D coordinates of proteins for most researchers. The CASP modelling competition 
has also revealed that homology modelling results can be verified and the models can be used in 
designing projects since biologically important regions are generally accurately modelled      
[53] ,[54]. Proteins, RNA and DNA sequences are archived in biological databases. To make it 
easy for the user to search through the immense data available in databases, database 
management systems like BLAST are used to perform a search. During a BLAST search, the 
query sequence is compared with other sequences in the database to identify similar or matching 
sequences. Scoring matrices are used to give a statistical value to ensure the accuracy of the 
selected sequence [55], [56].  
Structural and functional information of  nucleotides (DNA/RNA) and amino acid sequences are 
a result of evolution [51]. Due to mutations (insertions, deletions) and other evolutionary 
changes, sequences undergo changes in the arrangement of their residues. During this period, 
regions that code for properties that are important for the survival of the species are conserved 
by natural selection. Examples of residues that are conserved by natural selection include 
residues that code for functional and structural roles. These conserved regions can therefore be 
exploited by sequence alignment comparison to study their evolutionary relationships and to 
determine their degree of similarities from which their functionality can be extrapolated [55].  
Sequences whose residues are arranged in a similar way are concluded to be from the same 
family and to be coding for the same function, if the structure and function of one of the aligned 
sequences is known, its properties can be used to predict the structure and function of its 
homologs [57]. 
The number of possible ways in which a protein can fold in nature seems to be limited and the 
3D structure of proteins is more conserved that their sequences. So if a sequence of known 
structure shares a high (30 %) degree of residue similarity with another sequence of unknown 
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structure and function, the sequence with a known structure can be used as a template to guide 
in the calculation of a model structure for the sequence with unknown structure [41], [45], [50]. 
In this way sequence alignment can be used to characterise protein structure and function as well 
as to infer phylogeny. 
Detailed structural information on protein residues can be obtained from x-ray diffraction and 
NMR spectroscopy [45]. Obtaining protein structures using these methods can be time 
consuming and difficult [41], as a result only a few crystal structures have been developed and 
archived in the PDB. On the other hand sequence databases are expanding rapidly [53]. Since 
protein structure and function is encoded in their protein sequences, for a given protein 
sequence, bioinformatics tools like homology modelling can be used to calculate its 3D protein 
model by using coordinates of a protein with a known structure that shares more than 30% 
sequence identity [45], [41]. Functional properties of these models can then be characterised 
using docking studies.   
2.2. Databases 
Biological data is stored in computerized archives. This information in organised in such a way 
that information can be retrieved easily using a search criteria. A sophisticated search tool such 
as BLASTX [58] is usually used. Different types of data include primary data or raw data, 
secondary data and tertiary data. The primary data can be DNA, or amino acid sequences. The 
sequence information that comes from sequencing experiments is uploaded into primary 
databases by researchers. Examples include the GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) [59] made up of sequence data from authors, expressed 
sequence tag (EST), genome survey (GSS), SNP and GEO. Databases are crucial to 
bioinformatics research since they are a library of resources of information that is need for 
bioinformatics research. A newly acquired sequence (DNA or amino acid) can be uploaded into 
the database to compare it to other sequences in the database and gather information about it 
from its homologs [60]. So databases can be used for discovering new information. Some 
databases contain only DNA sequences while other contains only protein sequences. In protein 
databases, amino acids can be arranged to make domains which can be further arranged into 
motifs which are structural units of proteins. These constitute the secondary data which gives 
information on the protein secondary structure like alpha-helices or beta-strands. This 
information is stored in secondary databases which are curated and their content is controlled by 
the database developers. Examples include the NCBI (http://www.ncbi.nlm.nih.gov/) [61] which 
maintains the GenBank and also provides data retrieval and analysis systems, Protein, Refseq 
and RefSNP e.t.c. The tertiary data is related to the tertiary protein structure and it can be used 
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to predict the tertiary structure of the protein of interest. Databases are therefore divided into 
nucleotide and protein databases. The main nucleotide databases include EMBL (The European 
Molecular Biology Laboratory)  [62], GenBank (USA) and the DDBJ (DNA Data Bank of 
Japan) [63]. They are collectively called International Nucleotide Sequence Database (INSDC) 
[64]. Protein databases are composed of sequence and structural databases. Protein sequence 
databases include UniProt, PIR and SwissProt. Structural databases include the Protein Data 
Bank (PDB) [65], CATH and SCOPE. Other databases include protein interaction databases like 
the Biogrid and STRING. There are also some whole genome databases like ENSEMBL as well 
as specialised data bases like OMIM (Online Mendelian Inheritance of Man). Although they are 
independently made, databases are interconnected in such a way that a search in one can get you 
information from another. Sequence alignment is applied during a search [55], [61].  
2.3. Sequence analysis 
Comparing sequences is the first step in structural and functional analysis as well as in 
phylogenetic inference of protein sequences. Similarity between protein sequences indicates 
similarity in structure and it provides an opportunity for structural modelling when one of the 
sequences has a known 3D structure [57]. To clearly visualize regions of similarity and 
differences in protein sequences, they have to be aligned in such a way that matching residue to 
residue correspondence is established so that residue variations and similarities can be visualised 
easily. The maximum match is reached when the largest number of amino acids of one protein 
are matched with those from another protein while allowing for all possible deletions [66]. One 
of the most popular alignment approach for nucleotide and amino acid sequences is the dynamic 
programming developed in 1970 [66].  During database similarity search and sequence retrieval, 
pairwise sequence alignment is employed to retrieve homologous sequences. The same process 
is also used in multiple sequence analysis to align more than two sequences based on the 
similarity of their residues. Sequence alignment is carried out using sequence alignment 
algorithms. There are two types of sequence alignment methods; the local sequence alignment 
and global sequence alignment method. In local sequence alignment, two sequences are aligned 
in such a way that the highest number of local similar residues (segments) is aligned without 
trying to align the whole sequence. In global sequence alignment, two sequences are aligned 
from beginning to end, searching their entire lengths for an arrangement that will result in the 
maximum number of matching residues [56], [66]. These methods can be used in different 
situations. Since global alignment method compares full length sequences, it is appropriate for 
comparing short sequences that are closely related and are almost equal in length. When it 
comes to comparing distantly related sequences in which only short portions are related, the 
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local alignment method is preferred. This method can compare short conserved regions in 
sequences without aligning the rest of the sequence, so it can pick and align conserved areas and 
motifs in sequences that are distantly related and are not of the same length [55].   
Once the sequences are aligned, the best alignment has to be chosen. To guide in choosing the 
best aligned sequence and quantify the degree of similarity between aligned sequences, scoring 
or substitution matrices are used to assign scores for residue matches and substitutions [56]. A 
special score or penalty is usually given to account for deletions and insertions in the aligned 
sequences. Some scoring matrix take into consideration the frequency of amino acid substitution 
as well as the frequency of each amino acid that has occurred in the evolution of the sequence 
homologs [55]. The most common scoring matrices used in scoring multiple sequence 
alignments are BLOSUM (blocks amino acid substitution matrix) and PAM (point accepted 
mutations).  
The BLOSUM was developed as a series consisting of BLOSUM45, BLOSUM52, 
BLOSUM60, BLOSUM80 and BLOSUM90. BLOSUM series scores are based on comparison 
of blocks or local segment arrangement of residues of aligned sequences [56]. They were 
developed to account for distantly related sequences. Each series was developed using multiple 
alignments of sequences with a percent identity matching the relative BLOSUM number, for 
example, BLOSUM45 was developed using sequences of a sequence identity of about 45%. The 
series with the lowest BLOSUM number is more suitable for scoring alignment of sequences 
that are distantly related, while the series with the highest BLOSUM number is more suitable for 
scoring closely related sequences.  
PAM matrices are a series that was developed using very closely related sequence homologs. 
They were developed based on the replacement of an amino acid residue by another in a way 
that is acceptable by natural selection. The replacement of a single nucleotide by another is 
known as a point mutation. The PAM matrices were named with a number representing the 
number of mutations per 100 amino acid residues. In other words, this can be taken as a 
percentage of mutations. The lowest, PAM1, represents a 1% mutation per 100 amino acid 
residues. The PAM matrix followed by a high number is therefore suitable for scoring 
alignments that are distantly related, while the one followed by a low number is more suitable 
for scoring sequences that are closely related. Available PAM series range from PAM100, 
PAM120, PAM160, PAM200 and PAM 250 [55]. 
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2.4. Database Similarity Search and Sequence Retrieval 
Protein sequences represent a large part of data that is stored in biological databases. These 
sequences have to be retrieved from databases before they can be analysed. To retrieve the 
sequences of interest, the sequence in question, which is called a query, is submitted to the 
database of choice to search for homologous sequences. Pairwise sequence alignment is mainly 
employed during database sequence retrieval. A sophisticated search engine or database 
management system is usually used to carry out the search. These database management 
systems are required to be sensitive, selective and fast to be able to go through the amount of 
data stored in databases and carry out the required computation accurately. The Basic Local 
Alignment Tool (BLAST; https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) 
[67] is usually the tool of choice for database similarity search and sequence retrieval [55] and it 
is based on pair wise sequence alignment. BLAST uses a heuristic word method to quickly 
produce a pairwise sequence alignment. During a BLAST search, high scoring un-gapped 
sequence regions are found. These sequences are then weighed above a certain threshold at 
which pairwise alignment cannot occur by random change. BLAST results include percent 
sequence similarity and coverage as well as an E-value. The E-value is a statistical value that 
calculates the probability of a pairwise sequence alignment happening by chance. Databases that 
can be accessed by a BLAST search include the National Centre for Biotechnology Research 
(NCBI). BLAST program includes; 
BLAST-N : for nucleotide query to nucleotide database search, 
 BLAST-P : for protein query to protein database search, 
BLAST-X : which uses nucleotide as a query which is translated into six open reading frames to 
produce translated protein sequences. The translated sequences are then used as a query to 
search a protein database, 
TBLAST-N : which uses a protein sequence query to search a nucleotide database in which the 
nucleotide sequences have been translated into all the six open reading frames and finally the  
TBLAST-X : which accepts nucleotide sequences as a query. The sequences are then translated 
into all six open reading frames to search a nucleotide database that has sequences that have 
been translated into all open reading frames. 
Position-specific profile search method, PSI-BLAST is a BLAST variant which is able to detect 
distant homologs [67]. 
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When choosing the type of sequence to use in homology detection, it is advantageous to use 
protein sequences since their scoring matrix take into consideration physicochemical properties 
between the residues in addition to residue substitution and gap penalties [56], while nucleotide 
scoring matrix consider residue substitution and gap penalties only. 
The HHpred server (http://protevo.eb.tuebingen.mpg.de/hhpred) is also another program that 
can be used to identify template sequences. In addition to identification of sequences, it can also 
be used to calculate models in MODELLER using one of the templates it has identified. HHpred 
can identify distantly related sequences by searching a wide range of databases like the PDB, 
SCOP, Pfam, SMART, COG and CDD in a very short time. A pairwise sequence alignment 
search using a profile hidden Markov models (HMMs) is employed. The input is a query 
sequence or alignment with options to search in global or local alignment mode. An option for 
searching in PSI-BLAST iterations is also available. The output results include sequences 
(templates) with secondary structure annotation, an E-value and true probabilities. The 
probability value represents a principle measure of statistical significance at which the retrieved 
sequence (template) is a true positive homolog of the query sequence [48].  
Depending on the evolutionary relationship of the query sequence to the target homologs, one or 
both of the two programs can be used during sequence retrieval. Another program that can be 
used for searching for DNA and amino acid sequences is the LFAST for local similarity 
analyses [68]. 
2.5. Multiple Sequence Alignment (MSA) 
MSA  are an important step in protein structure and functional analysis as well as in 
phylogenetic studies since biological information can be revealed from conservation or 
differences within aligned positions [69].  In a MSA, homologous residues are represented in a 
given column and they can be super imposable in structure and they share a functional role. 
MSA also provide an advantage over pairwise sequence alignment since they make it easy to 
identify conserved regions, motifs, predict functional sites and protein function in the whole 
sequence family [41]. Different programs are available for multiple sequence analysis. These 
include PROMALS3D, MAFFT, CLUSTALW and T-COFFEE. In this project PROMALS3D 
and MAFFT shall be used for multiple sequence analysis and to calculate a phylogenetic tree 
with the best bootstrap values. 
PROMALS3D is a web server (http://prodata.swmed.edu/promals3d/promals3d.php) for 
construction of multiple sequence alignments for proteins and/ or structures [70]. It produces 
highly accurate alignments that have both sequence and protein structure consistency. The 
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server automatically identifies known 3D structure homologs for the query sequence and then 
combines both structure based constraints (from structural alignment) with sequence constraints 
to produce an alignment that has both sequence and structural information.  
MAFFT is also a web based (http://www.ebi.ac.uk/Tools/msa/mafft) MSA method that is based 
on the Fast Fourier Transformation (FFT). The FFT is an algorithm which increases the speed at 
which homologous sequences are detected by converting an amino acid sequence to a sequence 
made up of volumes and polarity values (electronegativity) of its residues. MAFFT also 
employs two different heuristic methods for reducing CPU time by using a simplified scoring 
system which also increases accuracy of sequence alignments that have multiple variations like 
large insertions or extensions and sequences of diverse evolutionary origin of matching length. 
These methods are the progressive method (FFT-NS-2) and the interactive refinement method 
(FFT-NS-i). Compared with other MSA  methods like CLUSTALW and T-COFFEE, MAFFT 
was demonstrated to be faster without losing accuracy [71] 
2.6. Phylogenetic analysis 
Products of evolution provide revelations to sources of diseases and they can be used to 
understand developing drug resistance in pathogenic microorganisms [72]. Homologous 
sequences frequently share the same structure and consequently the same function. Due to 
evolution, some homologous sequences have evolved as a result of speciation. Some 
homologous sequences have evolved to carry out the same function while others have evolved 
to carry out different functions. Homologous sequences that share a similar function in different 
species are called orthologs, and those that carry different functions are called paralogs and they 
are a result of gene duplication. To explore the structure and function of a sequence, the first 
step is usually to compare the query sequence with that of an evolutionarily related protein of 
known structure. Comparison of evolutionary related sequences has been used in identification 
of functional structures in genomes and in detecting homologs within and between genomes 
[73]. This comparison can be best assessed by using phylogenetic analysis to calculate an 
evolutionary tree that shows relatedness of species or certain genes that make the tree branches. 
From phylogenetic trees, relationships among copies of a gene or among loci of a multigene 
family can be inferred [74]. The separate branches represent the sources of sequences and they 
are called taxa. The point at which the taxa meet is referred to as a node and it represent a 
hypothetical common ancestral origin or a point at which a mutation was introduced and the 
species separated and evolved differently. The relative timing of species divergence or the 
lengths of internal branches determine the accuracy of the tree [75]. Branches from the same 
node form a clade representing descendants from a hypothetical common ancestor. Sequences 
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that are different from the rest of the test population form an out group. Phylogenetic results can 
reveal which sequences share more similarities and which sequences are different in the 
population [76]. Methods for estimating phylogenetic trees include neighbour joining (NJ), 
maximum parsimony (MP), maximum likelihood (ML) and Bayesian methods [74], [77].  
2.7. Homology Modelling 
Homology modelling is the calculation of the full 3D protein atomic model of unknown 
structure from its sequence by using the 3D structure (s) of a closely related (homologous) 
protein sequence as a template [76] and it  has been used for structural and functional studies of 
enzymes to identify drug targets [43], [45]. The biological function of a protein is determined by 
its structure, so construction of protein structures is important in gaining information about their 
function. Prediction of protein tertiary structure from their sequences is based on the observation 
that protein three dimensional structures tend to be more conserved than their sequence [78]. 
The most reliable method for predicting protein 3D structure is homology modelling which is 
also known as comparative modelling. The principle behind homology modelling is that proteins 
that share a high sequence identity often adopt the same 3D structure [41]. If an experimentally 
solved protein structure (template) is available, models can be calculated for homologous 
sequences (targets) with up to 30% sequence similarity or those that show structural similarity 
[41]. Steps involved in homology modelling are (i) template selection/identification of a known 
3D protein structure; (ii) sequence alignment of target and template proteins; (iii) 3D model 
construction of the target using the coordinates of 3D structure of the templates; (iv) model 
refinement, model evaluation and validation. These steps can be repeated until a good quality 
model is built [41]. 
2.7.1. Template Selection 
Template selection is the first and crucial step towards the calculation of a high quality model 
[79]. Currently the best way to predict the 3D structure of a model is to search for a homologous 
protein of known structure from protein structure databases like the PDB. Programs that can be 
used for template selection are BLAST and HHpred. More sophisticated methods for searching 
for a template include PSI-BLAST and profile-profile alignment. A sequence identity of at least 
30% between the template and target is considered high enough to give a reliable model during 
template selection [50]. If template and target sequence identity is below 40%, HHpred method 
has been shown to identify good templates but for template and target sequence identity above 
40% the BLAST method can be used for selecting the template [79]. Once a template has been 
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identified, a template and target sequence alignment can be made in preparation for homology 
modelling. 
2.7.2. Template and Target Sequence Alignment 
The accuracy and quality of a 3D protein model depends on the template and target sequence 
alignment. The quality of the template and target sequence alignment is therefore the most 
critical step in determining the quality of the final 3D model since it provides a framework from 
which backbones can be copied from the template to the target model structure [78]. Multiple 
sequence alignments of homologous sequences can be used to increase the accuracy and quality 
of the template and target sequence alignment. To improve the quality of the alignment, it may 
be necessary to manually edit the alignment [55]. Multiple sequence alignments also provide the 
additional option of using multiple templates in the alignment (if they are available) to improve 
the 3D model quality.  
2.7.3. Modelling 
The process of modelling involves copying the template’s backbone residue coordinates into the 
target sequence and calculating the actual 3D model of the target. Identical and aligned residues 
will assume the same side chain and main chain atoms while differences in aligned residues 
results in only the back bone atoms copied leaving the side chains to be added on a later step 
[55]. 
There are different programs available for use in homology modelling. Some of them are web 
based like the SWISS-MODEL (http://swissmodel.expasy.org/SWISS-MODEL.html) and 
HHpred (http://toolkit.tuebingen.mpg.de/hhpred). When using web based programs, the user 
inputs the query sequence and the program searches for the right template then constructs a 
model. Other model building programs are standalone programs like MODELLER which shall 
be employed in this research.  
The accuracy of the calculated model is usually compared to that of the template(s) by 
superimposition of the model and template structures. This process gives an RMSD (root-mean-
square-deviation) value. This value represents the root mean square deviation distance between 
corresponding Cα atoms and it can be ~1-2  [41]. Model quality assessment is usually carried 
out to determine the suitability of the calculated model to its intended applications. 
2.7.4. Model Evaluation and Validation 
The use of protein models for docking studies and other applications depends on their quality 
[45]. The application of the model determines the extent of the model quality and regions that 
33 
need to be modelled accurately [53]. There is currently no method available to consistently and 
accurately calculate protein 3D structure and there is also no method available to evaluate and 
calculate all the errors in a protein 3D model [80]. Models are therefore evaluated with a variety 
of protein model assessment methods to increase credibility of the model from complimentary 
results. Model evaluation results will determine if the model is good enough for the desired 
application or if further refinement process is necessary.  
2.7.5. Model Refinement 
Depending on the model evaluation results, some regions of interest may be highlighted as 
inaccurate and therefore may need further refinement. Sources of error occur in the template and 
target sequence alignment mainly due to deletions and insertions which result in gaps in the 
aligned sequences [57]. Since no residue information is available in the gaps, they cannot be 
modelled and they form loops in the model. To deal with this problem a loop modelling 
procedure may be necessary. The challenge with loop modelling is that there are currently no 
methods for loop modelling except to use techniques that search databases for parts that match 
the loop regions and try to fix the model. In the event that only the main chain atoms have been 
copied to the target, the missing residues must be calculated in those regions. Residues are 
important in determining protein and ligand interaction at the active site and so their geometry 
and energy constraints must be considered [52], [55] when loops are generated in this way. 
2.8. Methodology 
An overview of the methods and respective tools used during the different steps (sequence 
retrieval, multiple sequence alignment, phylogenetic analysis, homology modelling and model 
quality assessment and validation) leading to homology models is shown in Figure 2.0. 
Homologous sequences were retrieved from the NCBI and PDB database by a BLAST search 
while the HsCatB template was selected from a list of sequences produced by searching in the 
HHpred server. To determine which will give the best phylogenetic tree (based on bootstrap 
values), MAFFT and PROMALS3D MSA tools were both used to make MSAs. The MSA from 
PROMALS3D was used in calculation of homology models because PROMALS3D produces 
accurate alignments that have both sequence and protein structure information. A hundred 
models were calculated and from them the best models were chosen based on their low DOPE Z 
score using python scrips. The models were then evaluated using different model quality 
programs before they could be accepted for further application. 
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Figure 2.0: An overview of the methods used for sequence analysis and homology modelling. 
Both sequence and homology modelling were used for comparative analysis. 
2.8.1. Database similarity search and sequence retrieval 
A search for Trypanosoma brucei cathepsin B cysteine protease in the NCBI produced the 
crystal structure of Trypanosoma brucei procathepsin B (PDB ID 4HWY) as the latest addition 
to the list of results. Using default settings, the 4HWY sequence was used as a query to search 
for homologous sequences in a protein BLASTP search of the NCBI database. The main reason 
for using the 4HWY sequence as a query is that as a procathepsin, it contained both the full 
mature enzyme and the N-terminal prodomain. Since it contains a full mature enzyme sequence, 
it improved the search for finding other full mature enzyme sequence homologs. Trypanosoma 
cathepsin B-like (TbCatB) protease homologs from T. congolense, T. cruzi, T. vivax and T. 
brucei (PDB ID: 3HHI) were retrieved from the NCBI and PDB databases from the BLAST 
search. The HsCatB protease homolog (PDB ID: 3CBJ) was retrieved from a list of templates 
found by HHpred search using default settings. E-values lower than 1.0e
-5
 we considered to be 
significant when choosing sequences. Sequence coverage was also taken into consideration. 
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Sequences that were used in this project include two crystal structures (PDB ID: 3HHI and 
3CBJ) which were used as templates, and three target sequences (T. congolense, T. cruzi and T. 
vivax) whose 3D models were calculated. Since the occluding loop of Cathepsin B proteases can 
occur in a closed conformation and block access to the active site, it was important that the two 
selected crystal structures be in complex with inhibitors to ensure and open occluding loop. The 
two crystal structures were used individually as templates to make homology models for the 
target sequences. They were also used together (double templates) to make homology models 
for the same target sequences. This provided an opportunity to compare models from a single 
template and from a double template. Altogether, a total of 9 models were calculated. 
2.8.2. Multiple sequence alignment 
MSA of sequences was carried out using MAFFT and PROMALS3D programs. The 
PROMALS3D alignment was used in selecting sequences for template and target alignment 
prior to homology modelling (making PIR files) as well as in phylogenetic analysis, while the 
MAFFT alignment was used in phylogenetic analysis only. Default settings were used for MSA. 
The use of two alignment tools was carried out to determine which alignment will produce the 
best phylogenetic tree. 
2.8.3. Phylogenetic analysis in MEGA 
Phylogenetic studies were carried out using Molecular Evolutionary Genetic Analysis (MEGA) 
version 5.03 [81].  Molecular Evolutionary Genetics Analysis (MEGA) is software that provides 
tools for statistical analysis of DNA and protein sequences from an evolutionary point of view. 
These tools include sequence alignment tools, phylogenetic tree construction and viewing, 
evolutionary hypothesis tests, sequence divergence estimates, database sequence retrieval and 
options for generating data. When carrying out phylogenetic analysis in MEGA5, options for 
phylogenetic tree inference include the Maximum Likelihood (ML), Neighbour Joining (NJ), 
Minimum Evolution (ME) and Maximum Parsimony (MP) methods. Phylogeny tests can be 
carried out in bootstrap or branch-length tests. Options for substitution model (substitution type 
and model/method) are available to evaluate the fit of major models of nucleotide and amino 
acid substitutions. The user also chooses Rates and Patterns; gamma distributed (G), has 
invariant sites (I), and gamma distributed with invariant sites (G+I). More options include data 
subset to use (choose to use all sites, complete deletion of gaps, or partial deletion of gaps) and 
tree inference options  [81]. 
The maximum likelihood with a thousand boot strap tests method was used during phylogenetic 
tree construction. The model of substitution was set to amino acid, WAG+G substitution model. 
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The coverage cut off was set to 95 % for the Nearest-Neighbour Interchange (NIN) inference 
with a bootstrap value of 1000. Other parameters were left as default setting. Trees were 
estimated for both the MAFFT and the PROMALS3D alignment.  
2.8.4. Homology modelling 
Models were calculated for T.congolense, T.cruzi and T.vivax cathepsin B-like protease 
sequences since they did not have crystal structures. These models shall be evaluated with 
different model evaluation tools until satisfactory models are acquired before they can be used 
for further applications.  
The following sections explain activities that were carried out during homology modelling to 
calculate the 3D protein models. 
2.8.4.1. Template selection and multiple sequence alignment 
Two templates were used in the calculation of T.congolense, T.cruzi and T.vivax cathepsin B-
like protease models. One template was the T. brucei protease (PDB ID: 3HHI) template which 
was retrieved by the BLAST search during sequence retrieval. This is the structure of TbCatB in 
complex with the cysteine protease inhibitor CA074 [23]. The other structure was the HsCatB 
protease (PDB ID: 3CBJ) template which was chosen from a list of templates retrieved from 
searching in HHpred server (http://toolkit.tuebingen.mpg.de/hhpred). This is the structure of 
cathepsin B in complex with the T. cruzi inhibitor, chagasin [37]. It was important to choose the 
template in complex with an inhibitor to make sure that the occluding loop is modelled in the 
open position to allow for access to the active site by ligands during docking studies. 
2.8.4.2. Model building 
The MODELLER version 9.10 [82] program was used to carry out the calculation of the 3D 
protease models. Scripts that were used were obtained from the MODELLER manual and then 
edited to suit the available data and project needs. A hundred models were calculated for T. 
congolense, T, cruzi and T. vivax cathepsin B-like proteases using 3HHI and 3CBJ as templates. 
The best models were chosen based on their low DOPE Z scores before validation using 
MetaMQAPII, ANOLEA, PROCHECK and QMEAN6. The 3D model structures were 
visualized using PyMOL version 3.5. 
2.8.4.3. Model evaluation 
Before the models could be used for docking experiments, their quality had to be assessed and 
validated using different model quality assessment programs. The models were assessed and 
validated on the basis of their geometry using PROCHECK, and energy aspects using DOPE Z 
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scores, MetaMQAPII, ANOLEA and QMEAN6. The root mean square deviation (RMSD) 
between the main-chain atom of model and template was calculated by structural 
superimposition of templates and each model. 
2.8.4.4. Model quality evaluation programs 
1. DOPE Z scores 
It is a common practice to calculate a number of alternative models during structure prediction. 
From these models, the most accurate model is selected for subsequent assessments before it can 
be used for the desired application. The best models from MODELLER are chosen based on 
their DOPE Z score. The DOPE Z score is a measure of the model energy which is used to 
determine the stability of the model. A positive DOPE Z is likely to be a poor model while 
scores lower than -1 are likely to be close to the native like state of the protease. MODELLER 
provides a script that can be customised to calculate the DOPE-Z score. 
2. Root Mean Square Diviation (RMSD) 
To measure the similarity between two alternative conformations of a globular protein the root- 
mean-square deviation (RMSD) of virtual backbone Cα atomic coordinates is determined after 
optimal rigid body superposition. The RMSD measures the difference between the Cα atom 
positions between two proteins and so a smaller deviation means that the proteins are more 
spatially equivalent. In the macromolecule viewer PyMol [83], structural alignment can be used 
to determine the RMSD of two structures by superposition. To determine the RMSD, PyMol 
first carries out a sequence alignment and then tries to align the structures to minimise the 
RMSD. The output contains an executive RMSD for the two structures. The calculation can be 
restricted to a certain number of residues or the alignment of just the backbone atoms [84]. 
3. MetaMQAPII 
MetaMQAPII program is available as a free webserver (https://genesilico.pl/toolkit/) for protein 
model quality assessment. While most model quality assessment programs give a global 
assessment of the model, MetaMQAPII was developed to give the local residue assessment in 
the model. The server uses results from eight other model quality assessment programs 
(MQAP), (VERIFY3D, PROSA, BALA, ANOLEA, PROVE, PROQRES, REFINER, and 
TUNE) together with local residue features to assess a model’s local residues in relation to 
similar residues in native structures. MetaMQAPII can highlight single residue deviations in a 
model without the need for supplementary information. The input to the server is a protein 
model in a PDB format. The server outputs three files which are then sent by e-mail. The first 
file confirms the use of all the eight MQAPs for assessment. The second file contains raw data 
produced by the MQAPs and the MetaMPQAP predicted deviations together with the predicted 
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GDT_TS for the model. Last the model with its B-factor fields replaced by MetaMQAPs scores 
is produced in PDB format. This model can be visualised by a macromolecule viewer like 
PyMol and then coloured according to B-factor values. The resultant coloured model shows a 
spectrum of colours from blue, which correspond to regions of high accuracy, to red, which 
corresponds to low accuracy regions [85]. 
4. ANOLEA (Atomic Non Local Environment Assessment) 
ANOLEA is a server for protein structure assessment which calculates the energy of a protein 
chain. For each atom in the molecule it evaluates all the heavy atoms that are within a diameter 
of 7 Å, and belonging to an amino acid that is more than 11 residues away in the same amino 
acid chain or from a different chain. These are the “non-local environment (NLE)” of that 
particular heavy atom. The energy of each pairwise interaction in the NLE is taken from a 
distance dependent knowledge based mean force potential derived from a database of 147 non-
redundant amino acid sequences with a sequence identity below 25%. The amino acid sequences 
that make up the database were solved by X-ray crystallography and their resolution is lower 
than 3 Å. [80]. The input of the server is a PDB file with coordinates for each atom in the 
molecule together with identity of the protein chain to be assessed. Default setting can be set to 
user specifications to determine the threshold and the window average to perform the energy 
profile. The output includes a non-local energy profile plot for each amino acid of the molecule 
showing low energy (below zero and in green) representing favourable energy regions and high 
energy (above zero and in red) representing unfavourable energy regions. High energy regions 
correspond to errors and in some cases interacting protein regions. The ANOLEA server used in 
this project is part of the SWISS-MODEL work space for model structure assessment 
(http://swissmodel.expasy.org/workspace). 
5. QMEAN6 
The QMEAN (Qualitative Model Energy Analysis) server is a gateway to two model quality 
estimation scoring functions; QMEAN6 which is a composite scoring function for major 
geometrical aspects of a protein structure and QMEANclust which is a clustering based function 
[86]. 
The QMEAN6 function gives an estimate of both the global and local quality of the model; it 
can therefore be used in selection of models and for prediction of regions that might need further 
examination in models [86]. It estimates the global quality of the model from a linear 
combination of six structural properties. These properties include statistical potential of mean 
force, the solvation potential, the correlation of the predicted and calculated secondary structure 
and the solvent accessibility. The input model can be a single PDB format or multiple models as 
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zip or tar.gz file(s). The result gives an insight into the contribution of each property to the 
quality of the models in a table containing the QMEAN score and the values of the six 
properties. The output models are ranked from 0 to 1 based on the predicted global model 
reliability. An energy profile plot is also produced with scores ranging from zero (green) 
indicating stable regions, to 10 (red) indicating unstable regions. The output of QMEAN results 
also includes a model structure that predicts expected errors on a per residue basis. The model is 
coloured according to the QMEAN score where blue represent stable or reliable regions and red 
represent potentially unstable or unreliably modelled regions [87]. 
The QMEAN used in this project is part of the SWISS-MODEL work space for model structure 
assessment and it can be found at; (http://swissmodel.expasy.org/qmean.) 
2.8.4.5. Model stereochemistry evaluation programs 
Protein structures are bound to have both experimental and result interpretation errors. It is 
therefore necessary to have control measures and be able to assess the quality of the resultant 
structure or model [88]. In addition to values that measure the overall quality of the structure, 
(resolution, the R-factor, the R-indices and the ‘free R-value), stereochemistry measures that 
give information on the different regions of the structure can also be assessed.  
1. PROCHECK 
The PROCHECK is a suit of five programs that assesses the stereochemistry of a protein 
structure and also indicated residues in regions that might be wrong and need some attention 
[88]. The main input to the program is a structure file containing the coordinates. The stereo 
chemical information, bond lengths and bond angles used in protein assessment are derived 
from different research projects. The output of the PROCHECK program includes a 
Ramachandran plot. The Ramachandran plot shows the torsion angles for all residues in the 
structure with the exception of those at the chain end. PROCHECK produces a Ramachandran 
plot with a list of residues in the structure. The list of residues gives detailed information on the 
stereo chemical parameters and shows values that are wrong. A statistical plot of a percentage of 
residues in allowed regions, generously allowed regions and disallowed regions is produced. 
The program can be used in assessment of published structures, structures that are being solved 
and calculated model structures 
The PROCHECK program used in this project is part on the SWISS-MODEL work space for 
model structure assessment (http://swissmodel.expasy.org/workspace). 
 
40 
2.9. Results and Discussion 
2.9.1. Sequence retrieval 
TbCatB (PDB ID: 3HHI) protease sequence had a 99 % sequence identity to the TbCatB (PDB 
ID: 4HWY) and a 93% sequence coverage although they are from the same organism. The 93 % 
sequence coverage was due to 4HWY procathepsin protease sequence being longer because the 
mature protein was still attached to its propeptide. The HsCatB sequence scored the lowest 
sequence identity of 50% as a result of being distantly related to the trypanosome species. All 
the sequences had a significant E-value lower than 10e
-5
. A summary of the properties of the 
retrieved sequences is presented in Table 2.0 below. 
2.9.2. MSA and structural analysis 
Although PROMALS3D was used for homology modelling alignments (Appendix 1A), MAFFT 
program was used in the phylogenetic analysis alignment and in sequence comparison. The 
MSA (Figure 2.1 & 2.3) were viewed in Jalview [89] and they were coloured by percent 
identity. The mature form of cathepsin B polypeptide share the same sequence and structural 
features with other clan CA cycteine proteases and it is folded into two domains that form a V-
shaped active site cleft that contains the conserved catalytic triad Cys122(29), His282(199) and 
Asn302(219) (TbCatB numbering with HsCatB numbering in brackets), [23], [26], [29], [37]. 
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Accession 
number 
Organism Abbreviation % sequence 
identity 
% coverage E-value 
3HHI T. brucei TbCatB 99 93 0.0 
3CBJ H. sapien HsCatB 50 * 1e-53 
gb|ABY78821.1 T. congolense TcCatB 64 99 1e-157 
emb|CCC48215.1 T. vivax TvCatB 65 91 3e-145 
ref|XP_816569.1 T. cruzi TcrCatB 58 98 7e-136 
Table 2.0: Listed are retrieved TbCatB protease sequence homologs. Trypanosome homologs 
were obtained from NCBI using a Blast search while the human homolog was obtained using 
HHpred. Percent coverage and E-values are based on TbCatB structure 4HWY as the query 
sequence. * Similarity=1.049 (HHpred has no % coverage values) 
 
For this project, chain A of TbCaB protease sequence was used. This chain is made up of 
residues 78-335 which makes 257 amino acids of mature TbCatB [23]. Since there is no 
standard mature domain numbering, for clarity the TbCatB and other trypanosomatids 
sequences shall be numbered according to TbCatB numbering with HsCatB numbering in 
brackets. The crystal structure of the HsCatB protease sequence used in MSA and structural 
analysis was determined for an inactive recombinant enzyme variant. Mutations were introduced 
to change the catalytic Cys29 to Ala29 and the occluding loop Ser115 to Ala115 and H110 to 
Ala110 to prevent auto catalytic degradation during crystallization [37]. The sequence of the 
HsCatB starts with an Asp60p residue which is part of the propetide attached to the mature 
enzyme sequence. The mature domain of HsCatB consists of residues Leu1 to Asp254 [26]. The 
L-domain of HsCatB is made up of residues from the amino terminal end (excluding the first 10 
residues) up to Tyr148 (cathepsin B numbering), and by about the last four residues of the 
carboxy terminal while the R-domain is made up of the first 10 residues of the amino terminal 
and the carboxy terminal (excluding the last four residues) of the polypeptide chain  [25]. 
HsCatB protease contains an occluding loop made up of 22 residues from Ile105 to Pro126 in 
the L domain of the enzyme while the occluding loop of TbCatB is made up of residues from 
42 
Phe189 to Pro213 and has three extra residues [8], [23], [37]. The structure and function of 
TbCatB and HsCatB in the MSA shall be used to predict the structure and function of the 
aligned homologs. The focus of this alignment analysis shall be on regions that contribute to the 
protein and inhibitor interactions; the occluding loop, the active site residues and the catalytic 
residues. 
2.9.3. Inserts 
The MSA (Figure 2.1) shows that there is conservation of residues among the aligned homologs. 
There is also notable difference in the size of the sequences caused by residue insertions which 
have resulted in structural differences. Most notably the trypanosomatids have a longer N-
terminal than the HsCatB, a feature which was also observed by Kerr et al. The L-domain of the 
HsCatB has two insertions (Val50 and Met66) which are absent in the trypanosomatids 
cathepsin B proteases. The region from Ser90 to Arg101 forms a hairpin loop [25] in the 
HsCatB protease consisting of residues Gly91, Gly92, Leu93, Tyr94, Glu94, Ser96, His97, and 
Val98 that are not available in trypanosomatids cathepsin B. The occluding loop of TbCatB has 
three extra residues, Lys175, Tyr80 and Phe86 (TbCatB numbering) that are absent in HsCatB 
protease. The HsCatB protease also has three residues Lys141, Glu142 and Asp143 in the L 
domain hairpin loop which are not in any of the trypanosomatids proteases. There is also Val153 
insert in HsCatB which only corresponds to a Leu residue insert in T.congolense cathepsin B 
protease. 
2.9.4 The occluding loop  
The occluding loop region is made up of residues from Phe189(Ile105) to Pro213(Pro126)  [8], 
[23], [26], [37]. From the MSA, the occluding loop of TbCatB has Lys197, Try202 and Phe208 
residues which are not available in the HsCatB protease. The Lys197 residue is unique to 
TbCatB while the Try202 corresponds to Lys202, Asn202 and Leu202 in T. congolense, T.vivax 
and T. cruzi Cathepsin B like proteases respectively. The Phe208 residue of TbCatB respectively 
corresponds to Try208 and Met208 residues in T. congolense and T. vivax cathepsin B like 
proteases. The His194(110) and His-195(111) which contribute to the carboxypeptidase activity 
[23], [8] of cathepsin B proteases is highly conserved in all the sequences except in T. vivax 
cathepsib B like protease where His195(111) is substituted by a glycine residue. 
In HsCatB, a circular structure is formed when the occluding loop chain crosses over itself at 
Cys108 and Cys119 to form a disulphide bridge [25], [37]. The region leading to and from the 
occluding loop circle is flanked by conserved regions consisting of Pro106, Pro107 and Cys108 
leading to the circle and Pro117, Pro118 and Cys119 leading from the circle. These Pro-Pro-Cys 
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regions together with hydrogen bonds close to the disulphide bridge are suspected to contribute 
to the stability of the occluding loop [25], [37]. Between residues Ser206(Thr120) to 
Phe210(Gly123), the occluding loop of TbCatB contains a “FNFD” motif which corresponds to 
“GEGD” motif in HsCatB. In HsCatB the Gly121 and Gly123 on both sides of Glu122 makes 
this region more flexible than the corresponding Phe208 and Phe210 residues which come 
together with Phe189 to create a more stable S1’ opening in TbCatB. This difference may be 
may exploited to design more specific inhibitors for the TbCatB enzyme [23]. 
2.9.5. Active site residues 
The active site of cathepsin B cysteine proteases is made of a catalytic triad consisting of a 
cysteine residue that acts as a nucleophile and a histidine residue that acts as a general base and 
an asparagine residue that helps in the orientation of the histidine residue and also neutralizes 
the histidine charge during the intermediate state of hydrolysis of peptides [21]. The active site 
residues that make up this catalytic triad are Cys122(29) from the L-domain, His282(199) and 
Asn302(219) from the R-domain and it is situated in a cleft between the two domains that make 
up the protease [29], [23], [37]. The Asn302(219) side chain amide group is supported by N-H-π 
interactions from Trp304(221) and Trp308(225) [37]. Although they are not in the active site 
cleft, the His194(110) and His195(111) residues in the occluding loop are important for the 
endopeptidase activity of the enzyme since they are used for docking the C-terminal carboxylic 
group of the peptide substrate [22] by providing a positively charged anchor for the substrate 
carboxylic group [26].  
1. S2 subsite 
The S3 and S4 binding site of cathepsin B cysteine proteases are described as not real subsites 
but areas in which substrate residues find their favourable binding position [22]. The 3D 
complexes of TbCatB and epoxysuccinyl-based inhibitors CA030, CA074 and NS134 that were 
used during subsite determination revealed three subsites, S2, S1 and S1’ in which the substrate 
binds in an extended conformation[27], [22]. In HsCatB protease the S2 subsite is made up of 
residues Asp166(Tyr75), Pro167(76), Ala256(173), and Ala283(200) [25], and it determines 
specificity of the enzyme. In vertebrates, cathepsin B family members were defined as having an 
acidic residue at the bottom of the S2 subsite to accommodate basic P2 residues [23]. HsCatB 
protease has Glu245 at this position while TbCatB has Gly328. The corresponding position is 
occupied by Thr328, Gln328 and Ser328 in T. congolense, T. cruzi and T. vivax cathepsin B like 
proteases respectively.  
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The area around the S2 subsite of TbCatB protease is occupied by Asp166(Tyr75), 
Asp168(Ala77), Asp258(Ser175), as well as Asp327(Ser244) and Gly328(Glu245) at the bottom 
of the subsite [23]. The HsCatB Tyr75 residue is conserved in T. cruzi and T. vivax cathepsin B-
like proteases, but corresponds to Ala166 residue in T. congolense cathepsin B-like protease.  
Asp168(Ala77) residues correspond to Glu168 residue in T. cruzi and to Asp168 residues in T. 
congolense and T. vivax homologs. TbCatB and HsCatB residues Asp258(Ser175) corresponds 
to Gly258, Thr258 and Ser258 residues in T. congolense, T. vivax and T. cruzi protease 
homologs respectively. At the bottom of the S2 subsite, the Ser244 residue is conserved in T. 
congolense and T. vivax while Gly244 occupies the corresponding residue in T. cruzi.  
2. S1 subsite 
Interactions of peptidy substrate with cathepsin B-like enzyme subsites S1, S1’ and S2’ has not 
been fully predicted. The substrate P1 carbonyl group is predicted to bind to Cys122(29) and 
Gln116(23) in HsCatB [25], [27]. The MSA shows that both the catalytic Cys and the Gln 
residues are conserved in all the sequences.  
3. S1’ subsite 
The S1’ subsite is predicted to be around Val259(176), Phe263(180), Leu264(181),  
His282(199), and Trp304(221) [25], [27]. These residues are conserved in all the cathepsin B 
proteases used in this project.  
4. S2’ subsite  
The S2’ subsite is a shallow hydrophobic depression around the side chains of His194(110) and 
His195(111) [25], [27] and residues Trp308(225) and Phe263(180)[26]. These residues are 
highly conserved in all the sequences. 
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Figure 2.1: MSA of TbCatB protease homologs as predicted by MAFFT. Amino acids are 
highlighted according to percent agreement, > 80% in mid blue, > 60% in Light blue, > 40 % in 
light grey, and <= 40 % in white. 
 
2.9.6. Phylogenetic analysis 
To establish the evolutionary relationship of T. brucei cathepsin B-like protease, a phylogenetic 
tree (Figure 2.4) was calculated. The phylogenetic tree shows cathepsin B protease forming an 
out group and the Trypanosomes clustering together in one branch. This indicates that there are 
sequence differences between the HsCatB proteases and the trypanosome cathepsin B-like 
proteases. This observation is consistent with the sequence identity of 48.06%, 49.62%, 50.00% 
and 49.23% (Table 2.2) observed between the H. sapiens’ and T. brucei, T. congolense, T. cruzi 
and T. vivax respectively; while a sequence identity higher than 63% was observed among the 
trypanosomes. These differences can be exploited to identify potential inhibitors that are specific 
for trypanosomal cathepsin B proteases. Among the trypanosome taxa, T, cruzi forms a branch 
of its own, indication early evolutionary divergence from the other trypanosomes.  
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Protein ID S2 Subsite S1 Subsite S1’ Subsite S2’ Subsite 
Human 
cathepsin B 
Y75-P76-A173-A200-
E245 
C29-Q23 H199-V176-F180-
L181-W221 
H110-H111-
Phe180-Trp225 
T. brucei 
cathepsin B 
D166-D168-D258-D327-
G328 
C122-
Q116 
H282-V259-F263-
L264-W304 
H194-H195-
Phe263-Trp308 
T. 
congolense 
cathepsin B 
A166-D168-G258-S244-
T328 
 
C122-
Q116 
H282-V259-F263-
L264-W304 
H194-H195-
Phe263-Trp308 
T. cruzi 
cathepsin B 
Y166- E168-S258-G327-
Q328 
C122-
Q116 
H282-V259-F263-
L264-W304 
H194-H195-
Phe263-Trp308 
T. vivax 
cathepsin B 
Y166- A168-T258-S327-
S328 
C122-
Q116 
H282-V259-F263-
L264-W304 
H194-H195-
Phe263-Trp308 
Table 2.1: Shown are the Subsite residues for the S2, S1, S1’and S2’ subsites of the homologs. 
For clarity the trypanosomatidae homologs were numbered according to TbCatB numbering.  
2.9.7. Homology Modelling 
Homology models were calculated for T. congolense, T. cruzi and T. vivax cathepsin B-like 
proteases. The best models were selected based on their model evaluation results from different 
model evaluation methods. The following steps demonstrate the procedure followed during 
homology modelling. 
2.9.8. Template selection 
As previously stated, template selection is a very important step in homology modelling since 
the template (s) determine (s) the quality and accuracy of the 3D model. Two protease crystal 
structures were identified and used as templates for calculation of the models. 
These are TbCatB, (PDB ID: 3HHI) and the HsCatB protease, (PDB ID: 3CBJ). The identified 
3HHI template is reported as the first structure of TbCatB in complex with the cathepsin B 
selective inhibitor CA074 [23]. This structure was determined by X-ray Crystallography at 
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resolution of 1.60Å. The HsCatB protease structure is in complex with the T. cruzi inhibitor 
chagasin. This structure was solved by X-ray diffraction at 1.80 Å [37]. 
It was important to use templates in complex with inhibitors because it ensured that the resulting 
model will be calculated with the occluding loop in an open conformation. The occluding loop 
of TbCatB proteases can occur in both open and closed conformation. When in open 
conformation, it allows access of substrates to the S2 subsite which determines specificity of the 
protease. 
 
Figure 2.2: Showing the superimposed TbCatB (Cyan blue) and HsCatB (light orange) protease 
structures. The active site Cys122(29) residues are shown as yellow sticks and the His194(110) 
and His195(111) are shown in purple. Residues Gly328(Glu245) are shown in red and green 
respectively. Gly residue is much smaller than the Glu residue, creating a deeper S2 pocket. 
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Figure 2.3: MSA of TbCatB protease homologs as predicted by PROMALS3D. Amino acids are 
highlighted according to percent agreement, > 80% in mid blue, > 60% in Light blue, > 40 % in 
light grey, and <= 40 % in white. PIR alignments were made from this MSA for homology 
modelling.                                               . 
 
 
Figure 2.4 Phylogenetic analyses of TbCatB homologs. The tree shows distinct clustering of 
trypanosomatidae family homologs from the HsCatB protease homolog. 
 
When the occluding loop is in closed conformation, it restricts access to the S2 sub site. Since 
the models are going to be used for docking studies, they have to be modelled with the 
occluding loop in open conformation to allow ligand access to the active site. 
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In addition to their good resolution, the templates were chosen based on their high sequence 
identity to the targets. The quality of the templates was accessed using PROCHECK, ANOLEA 
and QMEAN.  
Template Resolution [Å] Target Sequence identity (%) 
 
3HHI 
 
1.60 
T. congolense 66.41 
T. cruzi 63.57 
T.vivax 68.22 
 
3CHJ 
 
1.80 
T. congolense 49.62 
T. cruzi 50.00 
T.vivax 49.23 
Table 2.2: Listed are the template and target sequence identities used in homology modelling of 
TbCatB homologs. The sequence identity of the two templates is 48.06 %. 
 
The results for templates and targets sequence identity (Table 2.2) show that all the sequences 
are homologous. A sequence identity of 66.41%, 63.57% and 68.22% was obtained between the 
TbCatB (PDB ID: 3HHI) template and the targets, T. congolense, T. cruzi and T. vivax  
respectively while lower sequence identities of 49.62 %, 50.00% and 49.23% were obtained 
between the HsCatB (PDB ID:  3CBJ) template and the respective targets. Good quality models 
can be obtained from these sequences since their percent identity is higher than the 30% 
required for making a good quality model. Models build from these sequences can also be used 
to assess the protease potential as a drug target. Sequence identities of 25 to 50% identities can 
be used to test if a protease can be used as a drug target [41].  
2.9.9. Template evaluation and validation 
The chosen templates quality was evaluated using model quality evaluation tools. This was done 
to make sure that the template structures had no unstable regions that would later be inherited by 
the models. Model evaluation programs PROCHECK, ANOLEA and QMEAN were used in the 
evaluation of the template structures. The results are shown in Figures 2.6 to 2.8. Table 2.3 
shows PROCHECK results as obtained from the Ramachandran plot statistics for the two 
templates used and the homology models.  
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Structure 
(protease) 
Residues in 
most favoured 
regions [A,B,L] 
Residues in 
additional 
favoured regions 
[a,b,l,p] 
Residues in 
generously allowed 
regions [~a, ~b, ~l, 
~p] 
Residues in 
disallowed 
regions 
TbCatB (3HHI 
template) 
88.0 % 11.5 % 0.5 % 0.0 % 
HsCatB (3CBJ 
template) 
85.3 % 14.3 % 0.3 % 0.0 % 
Table 2.3: Shown are the Ramachandran plot statistics as produced by PROCHECK for each of 
the templates used in homology modelling. 
 
The superimposed structures of TbCatB (PDB ID: 3HHI) and HsCatB B (PDB ID: 3CBJ) 
templates (Figure 2.5) show that the occluding loop of the two templates is not open to the same 
degree. The HsCatB crystal structure (3CBJ) is in complex with the T. cruzi inhibitor chagasin 
while TbCatB (3HHI) is in complex with the smaller cysteine protease inhibitor CA074. The 
chagasin inhibitor has therefore opened the occluding loop of HsCatB much wider than the 
smaller CA074 inhibitor has done for TbCatB. The occluding loop can move and open to 
different degrees depending on the size of the bound substrate [37]. Since the occluding loop of 
the models should be in the open conformation for docking studies, models calculated from 
these two templates are expected to adopt the orientation of the respective template and their 
occluding loop should be in the same conformation as the respective templates. We are still to 
find out the occluding loop conformation that will be adopted by models calculated using a 
combination of the templates. Stereochemistry results for the two templates (Figure 2.6) show 
all the residues of the templates are in favoured regions. The ANOLEA validation and QMEAN 
energy profile also confirm that the templates are stable and of acceptable quality. ANOLEA 
and QMEAN results for HsCaB (PDB ID: 3CBJ) template (Figure 2.8) indicate the region 
between Val112 and Pro117 as having unfavorable energy and unstable respectively. This can 
be of no major concern as long as it is not inherited by the models, especially since it is close to 
the His110 and His111 residues that are participant in exopeptidase activity. 
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Figure 2.5: Superimposed (A) ribbon and (B) cartoon template structures of PDB ID: 3HHI 
(purple) and 3CBJ (blue). The occluding loop of 3CBJ is open wider than that of 3HHI due to 
the large chagasin inhibitor. 
 
 
Figure 2.6: QMEAN energy profile for (A) 3CBJ and (B) 3HHI template. The QMEAN scores 
are colour coded from blue (stable) to red (unstable) regions. 
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Figure 2.7: PROCHECK analysis for (A) HsCatB (PDB ID: 3CBJ), and (B) TbCatB (PDB ID: 
3HHI) templates. The PROCHECK plot statistics shows 100 % of residues are in favoured 
regions for both the templates. 
2.9.10. Homology modelling results and discussions 
All the 3D models were calculated using MODELLER version 9.10 by customising 
MODELLER scripts to meet the project needs. Two template and inhibitor complexes were 
identified and they were both used to make the template and target sequence alignment from 
which the models were calculated. For each model a hundred models were made, out of which 
the best three models were selected based on their low DOPE Z score. The models were then 
validated using MetaMQAPII, PROCHECK, ANOLEA and QMEAN model evaluation 
programs. After model validation, the model that performed best was chosen as the cathepsin B-
like protease model for docking experiments. 
2.9.11. Model validation 
The best three models were selected using a python script which selected the models based on 
their DOPE Z scores. A DOPE Z score lower than -1 score is preferred for models since it 
means that the model has a low energy and therefore it is in its more stable condition. The cut 
off point for accepting a model is set at -0.5 after which models with a higher DOPE Z score are 
likely to be poor models. To determine the similarity between the homology models and the 
template crystal structures the Root Mean Square Diviation (RMSD) was measured by 
superposition of the backbone atoms of the homology models with those of the crystal structures 
in PyMol [83]. An arbitrary RMSD cut off value of 3Å is usually used by most researchers [84]. 
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Table 2.4 and 2.5 respectively shows the DOPE Z scores and the RMSD values of the models. 
Lower RMSD values were obtained for models when superimposed to the 3HHI template than 
the 3CBJ template. The models are therefore more similar to TbCatB structure that to HsCatB 
structure. These results are in agreement with the phylogenetic and percent identity results.  
 
Figure 2.8: ANOLEA evaluation and QMEAN6 energy profile for PDB ID: 3HHI. ANOLEA 
score values greater than zero correspond to high energy regions / erroneous possible 
interactions. QMEAN scores are color coded from green (stable) to red (unstable) regions. 
QMEAN scores above 2 represent high energy (unstable) region  
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Figure 2.9: ANOLEA evaluation and QMEAN6 energy profile for PDB ID: 3CBJ. ANOLEA 
score values greater than zero correspond to high energy regions / erroneous possible 
interactions. QMEAN scores are color coded from green (stable) to red (unstable) regions. 
QMEAN scores above 2 represent high energy (unstable) region. 
 
Figure 2.10 shows that the models adopted the 3D orientation of the templates from which they 
were calculated. In Figure 2.11, the occluding loop of the models that were calculated form a 
combination of the templates, adopted the 3HHI occluding loop template orientation. This might 
be because the occluding loop is less strained in this position which is nearer the closed 
conformation and therefore it is a more favourable position. The occluding loop of models 
calculated from the 3CBJ template is open wider than that of models calculated from the 3HHI 
template and from a combination of the templates. The active site of the 3CBJ template models 
is therefore more exposed than that of the other template models, a feature which might make it 
easier for docking of large molecule inhibitors.………………………………………………. 
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Structures 3HHI template 3CBJ template 3HHI_3CBJ template 
TcCatB - 1.12 - 0.90 - 1.01 
TcrCatB - 0.59 - 0.30 - 0.55 
TvCatB - 1.20 - 1.10 - 1. 39 
Table 2.4: Listed are the DOPE Z-scores of the models. The DOPE Z-scores of the templates 
were – 1.44 and – 1.14 for 3CBJ and 3HHI respectively. 
 
Structures 3HHI template 3CBJ template 3HHI_3CBJ template 
TcCatB 0.173 0.240 0.281_0.536 
TcrCatB 0.262 0.312 0.303_0.537 
TvCatB 0.196 0.251 0.262_0.578 
Table 2.5: Listed are the RMSD values showing the similarity between the homology models 
and the templates. The RMSD of the templates was found to be 0.668.  
 
Figure 2.10: Superimposed ribbon structures of templet PDB ID: (A) 3CBJ (blue) and (B) 3HHI 
(purple) with models for T. congolense (yellow), T. cruzi ( green) and T. vivax (orange) 
calculated from each template. 
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Figure 2.11: Superimposed ribbon structures of templet PDB ID: (A) 3CBJ (blue) and (B) 3HHI 
(purple) with models for T. congolense (yellow), T. cruzi ( green) and T. vivax (orange) 
calculated from a combination of the templates. 
 
Figure 2.12: QMEAN energy profile for T. congolense cat B-like models built from (A) 3CBJ, 
(B) 3HHI, (C) Double template and (D) MetaMQAPII for double template models. The 
QMEAN/MetaMQAPII scores are color coded from blue (stable) to red (unstable) regions. 
The MetaMQAPII server went down before results for single template models and template 
structures could be acquired. MetaMQAPII energy profiles were acquired only for the double 
template models. These results are shown alongside QMEAN energy profiles for all the 
homology models.  
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Figure 2.12 shows the QMEAN energy profile showing per residue predicted errors for T. 
congolense models. The models are coloured according to the QMEAN score where blue 
represents stable regions and red represents unstable regions [87]. Model (A); calculated from 
the HsCatB (PDB ID 3CBJ) template has an unstable region in the occluding loop region. 
 
Figure 2.13: PROCHECK analysis for T. congolense cat B-like models built from (A) 3CBJ, (B) 
3HHI and (C) Double template(s). The PROCHECK plot statistics shows 100%, 99.5% and 
99.6% of residues are in favoured regions 3CBJ, 3HHI and double template models 
respectively. 
This is of major concern since the occluding loop is participant in substrate binding. Although 
model (B), calculated from the T. brucei (3HHI) template has some unstable region at the 
beginning of the occluding loop, the model can still be reliable since the affected area is not 
directly involved in substrate binding. Out of these three models, the model that scored the best 
according QMEAN profile is model (C), which was calculated from a combination of the two 
templates. Stereochemistry results obtained for T. congolense cat B models (Figure 2.13) show 
that all the residues are in allowed regions for the model calculated using template 3CBJ. The 
model calculated using 3HHI template has Arg12 residue in a disallowed region while the 
model calculated using both templates has Arg12 and Asp148 residues in disallowed regions. 
The models calculated from these templates therefore respectively have 99.5% and 99.6% of 
residues in favoured regions.  ANOLEA evaluation and QMEAN6 energy profiles (figures 2.14-
2.16) rates all the models as good models.  
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Figure 2.14: ANOLEA evaluation and QMEAN6 energy profile for T. congolense cat B-like 
protease model built from 3CBJ template. ANOLEA score values greater than zero correspond 
to high energy regions / erroneous possible interactions. QMEAN scores are color coded from 
green (stable) to red (unstable) regions. QMEAN scores above 2 represent high energy 
(unstable) region 
 
Figure 2.15: ANOLEA evaluation and QMEAN6 energy profile for T. congolense cat B-like 
protease model built from 3HHI template. ANOLEA score values greater than zero correspond 
to high energy regions / erroneous possible interactions. QMEAN scores are color coded from 
green (stable) to red (unstable) regions. QMEAN scores above 2 represent high energy 
(unstable) region. 
59 
 
Figure 2.16: ANOLEA evaluation and QMEAN6 energy profile for T. congolense catB-like 
model built from a combination of 3HHI and 3CBJ templates. ANOLEA score values greater 
than zero correspond to high energy regions / erroneous possible interactions. QMEAN scores 
are color coded from green (stable) to red (unstable) regions. QMEAN scores above 2 represent 
high energy (unstable) region. 
 
Figure 2.17: QMEAN energy profile for T. cruzi cat B-like models built from (A) 3CBJ, (B) 
3HHI, (C) Double template and (D) MetaMQAPII for double template models. The 
QMEAN/MetaMQAPII scores are colour coded from blue (stable) to red (unstable) regions. 
Model structures showing the QMEAN profile of T. cruzi models are shown in Figure 2.17. All 
the calculated models are stable and of high quality.  
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In Figure 2.18, we can see the stereochemistry results of the models calculated for T. cruzi. 
These results show Asn206 and Asp59 residues in disallowed regions leaving 98.8% of residues 
in allowed regions for the model calculated with the 3CBJ template (Figure 2.18. A). In the 
model calculated with both the templates (Figure 2.18. C), Asp84 residue in observed to be in 
disallowed area. 100% of residues were modelled in favoured regions for the model calculated 
from 3HHI template.  
 
Figure 2.18: PROCHECK analysis for T. cruzi cat B-like models built from (A) 3CBJ, (B) 3HHI 
and (C) double template models. The PROCHECK plot statistics shows 98.8 %, 100 % and 99.6 
% of residues are in favoured regions for 3CBJ, 3HHI and double template models respectively. 
ANOLEA evaluation and QMEAN6 energy profile (Figures 2.19-2.11) are picking some 
unstable regions in all the models although not necessarily at the same regions. These errors 
were not highlighted by other model quality and evaluation programs so this models can be used 
for further applications. 
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Figure 2.19: ANOLEA evaluation and QMEAN6 energy profile for T. cruzi cat B-like protease 
model built from 3CBJ template. ANOLEA score values greater than zero correspond to high 
energy regions / erroneous possible interactions. QMEAN scores are color coded from green 
(stable) to red (unstable) regions. QMEAN scores above 2 represent high energy (unstable) 
region. 
 
Figure 2.20: ANOLEA evaluation and QMEAN6 energy profile for T. cruzi cat B-like protease 
model built from 3HHI template. ANOLEA score values greater than zero correspond to high 
energy regions / erroneous possible interactions. QMEAN scores are color coded from green 
(stable) to red (unstable) regions. QMEAN scores above 2 represent high energy (unstable) 
region. 
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Figure 2.21: ANOLEA evaluation and QMEAN6 energy profile for T. cruzi cat B-like model 
built from a combination of 3HHI and 3CBJ templates. ANOLEA score values greater than zero 
correspond to high energy regions / erroneous possible interactions. QMEAN scores are color 
coded from green (stable) to red (unstable) regions. QMEAN scores above 2 represent high 
energy (unstable) region. 
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Figure 2.22: QMEAN energy profile for T. vivax cat B-like models built from (A) 3CBJ, (B) 
3HHI, (C) Double template and (D) MetaMQAPII for double template models. The 
QMEAN/MetaMQAPII scores are color coded from blue (stable) to red (unstable) regions. 
Predicted residue errors for T. vivax models (Figure 2.22) show that the models calculated using 
3CBJ template is the most reliable one as shown by the lack of unstable (red) regions in the 
model (Figure 2.22. A). The QMEAN energy profile for models calculated from 3HHI template 
and a combination of the templates have unstable residues in parts of the occluding loop that 
take part in substrate binding. But the energy MetaMQAPII profile for the double template 
model (Figure 2.22 D), does not show unstability at the same region for the same model.  
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Figure 2.23: PROCHECK analysis for T. vivax cat B-like models built from (A) 3CBJ, (B) 
3HHI and (C) double template models. The PROCHECK plot statistics shows 99.5%, 99.5% 
and 99.6 % of residues are in favoured regions for 3CBJ, 3HHI and double template models 
respectively. 
The results for stereochemistry analysis of T. vivax models (Figure 2.23) show that 99.5% of the 
residues are in favored regions for the model calculated using 3CBJ template. This model has 
Asn216 and Thr68 residues modelled in disallowed regions. The model calculated from 3HHI 
template has Asn227 in disallowed region and 99.5% of residues in favored regions. Using both 
templates to calculate the model resulted in 99.6% of residues modelled in favored regions while 
Asn229 was modelled in a disallowed region.  
Although ANOLEA evaluation and QMEAN energy profile indicate that all the models are 
reliable (Figure 2.24-2.26), the most stable models is that calculated from a combination of the 
templates (Figure 2.26). Both ANOLEA and QMEAN results show that regions around residues 
104-109 and 114-120 are unfavored and unreliable for the model calculated from 3CBJ template 
(Figure 2.24). These regions are very close to the His-194(110) and His-195(111) residues that 
are responsible for the exopeptidase activity of cathepsin B enzymes. However since the error 
was not picked by other models evaluation programs, this models can still be relied on for 
further applications. 
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Figure 2.24: ANOLEA evaluation and QMEAN6 energy profile for T. vivax cat B-like model 
build from 3CBJ template. ANOLEA score values greater than zero correspond to high energy 
regions / erroneous possible interactions. QMEAN scores are color coded from green (stable) to 
red (unstable) regions. QMEAN scores above 2 represent high energy (unstable) region. 
 
Figure 2.25: ANOLEA evaluation and QMEAN6 energy profile for T. vivax cat B-like model 
build from 3HHI template. ANOLEA score values greater than zero correspond to high energy 
regions / erroneous possible interactions. QMEAN scores are color coded from green (stable) to 
red (unstable) regions. QMEAN scores above 2 represent high energy (unstable) region. 
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Figure 2.26: ANOLEA evaluation and QMEAN6 energy profile for T. vivax cat B-like model 
build from a combination of 3HHI and 3CBJ templates. ANOLEA score values greater than 
zero correspond to high energy regions / erroneous possible interactions. QMEAN scores are 
color coded from green (stable) to red (unstable) regions. QMEAN scores above 2 represent 
high energy (unstable) region. 
2.9.12. Comparative structural analysis of the active site 
As stated in chapter 1 (1.7.4), substrate specificity is determined by interactions between the 
enzymes and the substrate residues at the active site. Differences at the active site may therefore 
be used to design target specific inhibitors. The S2 subsite of cathepsin B proteases determines 
selectivity [90] and the bottom of TbCatB subsite is occupied by a Gly328 residue. This small 
residue allows the S2 subsite to be deep enough to accommodate large P2 subsites. The same 
position is occupied by the larger Glu245 residue in HsCatB, which results into a shallower S2 
pocket [23]. Another notable difference between TbCatB and HsCatB is the extra flexibility in 
the occluding loop of HsCatB due to glycine residues on both sides on Glu122 in the “GEGD” 
motif between residues 206(120) to 210(123). 
The flexibility allows the Glu122 to move in and out of the S1’ subsite easily. The same 
movement is restricted for the Asn209 residue in the corresponding “FNFD” motif in TbCatB. 
The Phe208 and Phe210 residues flanking the Asn209 residue are attached to the Phe189 
residue of the occluding loop, creating a stable opening around the S1’ subsite. In fact Kerr et al 
states that this feature could be used to design inhibitors targeting this enzyme. In addition to the 
Pro106-Pro107-Cys108 and Pro117-Pro118-Cys119 regions that confer stability to the 
occluding loop in HsCatB [25], at low pH additional stability of this loop is due to two salt 
bridges between (His110 and Asp22) and (Arg116 and Asp224) whose disruption resulted in 
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increased endopeptidase activity [23]. In our MSA (Figure 2.1), His110 and Asp22 are 
conserved in all the sequences, Arg116 corresponds to Tyr202 [23] and Asp224 corresponds to 
Glu307 in TbCatB. The biochemical roles of these substitutions have not been investigated yet, 
leaving room for future research. The His110 and Asp22 interaction has however been exploited 
to develop the specific cathepsin B inhibitor CA-074, and the removal of His110 residue has 
been correlated with improved inhibitor binding [37]. 
2.10.  Conclusion 
Different model quality evaluation programs were used so that a model could be disqualified 
based on their combined results. The DOPE Z scores and the RMSD (RMS) values of the 
calculated models indicate that the models are of acceptable energy (stability) and fold 
(conformation). Based on the RMSD values the models adopted the orientation of the TbCatB 
crystal structure more than they did the human crystal structure. Even models made from a 
combination of the two templates adopted the occluding loop conformation of TbCatB template. 
These results are expected since they shared a higher sequence identity (see Table 2.2) with the 
TbCatB sequence than with the HsCatB sequence. The different MQAPs used did not single out 
a certain model as unacceptable or unreliable. The MSA made from MAFFT program produced 
a phylogenetic tree of higher bootstrap values that the one from PROMALS3D (see Appendix 
2A). The overall conclusion reached from these models is that they are of acceptable quality and 
they can be used for docking studies. To determine the effect of the difference in the residues at 
the bottom of the S2 pocket, molecular docking and molecular dynamics simulation studies shall 
be carried out in the next chapters. These studies are expected to shed light on the effect of 
residue variations at the active site on substrate interaction. These differences present an 
opportunity to design inhibitors that are specific for TbCatB and other trypanosome cathepsin B 
proteases.  
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Chapter 3.      
3.1. Molecular Docking 
In chapter 2, sequence and structural comparisons of Trypanosoma brucei cathepsin B (TbCatB) 
and homologous proteins from human Cathepsin B (HsCatB), Trypanosoma congolense 
cathepsin B (TcCatB), Trypanosoma cruzi cathepsin B (TcrCatB), and Trypanosoma vivax 
cathepsin B (TvCatB) were looked at. Major differences were noted, especially in the S2 subsite 
where TbCatB has the smaller Gly328 residue while HsCatB has the larger Glu245 residue at 
the same position resulting in a larger S2 pocket in TbCatB. We also noted differences in the 
occluding loop region where TbCatB has a “FNFD” motif which gives it stability and results in 
a stable S1’ subsite opening. HsCatB has a “GEGD” motif at the same position and this motif 
makes this region flexible and results in an unstable S1’ subsite in HsCatB. This differences 
present an opportunity for designing target specific compounds [23]. In this chapter, how the 
variations in the active site of these homologous proteins affect binding of substrates is 
explored.  
A known cysteine protease inhibitor CA074 and a nitrile inhibitor were used for docking 
validation and to investigate interacting residues in TbCatB and HsCatB respectively. 
The effect of these interactions can be used to determine the properties of drugs that can be 
developed to target TbCatB. As previously stated in our problem statement (chapter 1.8), 
currently used drugs were developed for their anti-parasite properties without knowledge of the 
biochemical pathways of the parasite. They therefore lack specificity and are toxic to the host 
[8]. Molecular docking studies were used to investigate the active site residues of TbCatB and 
its homologs and to screen the South African Natural Compounds Database (SANCDB) [49], 
https://sancdb.rubi.ru.ac.za for possible leads. Molecular dynamics (MD) studies of the most 
promising compound(s) were carried out to determine the stability of their interactions with the 
substrates and to understand how the interacting residues fluctuate over time under conditions 
close to physiological ones.  
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3.2. Introduction 
Proteins function by interacting with each other, biomolecules like DNA, RNA, and with small 
molecules. Understanding these interactions can reveal the mechanism by which they function 
and can also reveal information on how they can be exploited for functional and therapeutic 
purposes [91], [92], [93]. In protein-ligand docking, the aim is to predict and determine the 
conformations and binding affinities of complex structures that are formed during interaction of 
a ligand and a target protein of known crystal structure or a homology model [94], [95]. In drug 
discovery, the correct prediction of binding of small molecules (ligands) to target proteins is 
important because it can be used to screen large databases of compounds to obtain leads for drug 
design [95]. These compounds could be sourced from corporate or commercial compound 
database, or from virtual compounds libraries [96] like the South African Natural Compounds 
Database (SANCDB)[49] used in this study.  
There have been several successful cases in which novel ligands have been identified using 
receptor virtual screening methods. Examples of these include identification of an 
indoloquinazolinone derivative from 400 000 molecules as a potent inhibitor of human casein 
kinase II using a homology model, and the novel 2-amino-4-heteroaryl-purimidine inhibitors of 
CDK2 that were identified from a commercial library of 50 000 compounds  [5].  
Protein - ligand docking is the process of predicting a protein and ligand complex and its free 
binding energy using experimentally determined 3D complex structures or free structures and 
homology models [94] , [9]. During docking, the best orientation and conformation of the ligand 
is searched within the binding pocket of a protein crystal structure or model in a process known 
as posing [99]. Early docking processes historically only involved the use of a protein and 
ligand as rigid components. However current methods view the protein as a body made up of 
different conformations in equilibrium and a flexible ligand. A number of alternative protein and 
ligand complex conformations are usually generated and then ranked according to ligand 
binding affinity.  
The process of docking therefore involves a search algorithm and a scoring function [94], [99]. 
The search algorithm should efficiently generate a broad range of plausible binding 
conformations while the scoring function should represent the thermodynamics of all the 
protein-ligand complexes well enough to separate and rank the best complexes from the rest. 
Protein-ligand docking is used in structure-based drug design and discovery research to study 
the mechanisms of recognition and interaction between protein substrates and inhibitors and to 
elucidate fundamental biochemical processes [94], [99]. Protein - ligand docking is therefore an 
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ideal tool to use in virtual screening of large databases of compounds (small molecules) if a 
target structure is available. It can be used to discriminate between potential strong binding 
compounds and non-binders, speeding up the process of obtaining leads for further drug 
development [100]. Docking has been used in many situations - anti-gout [45], M. tuberculosis 
[43] and malaria [101] research – to name a few to search for potential drug leads. This 
highlights the importance of accurate prediction of the binding modes of the ligand to the 
protein. Prior knowledge of the binding site increases docking efficiency since the search space 
is already narrowed down. Comparing the target protein with protein-ligand co-crystals of 
proteases that share the same function can be used to obtain information about the binding site. 
Online servers like GRID, POCKET, SurfNe, PASS and MMC can also be used to obtain the 
binding site for docking [99]. 
3.3. Docking Algorithms 
The root-mean-square deviation (RMSD) between the predicted ligand pose and the actual 
position of the ligand in crystal structure complex is used to measure the accuracy of the 
docking. To reduce difficulties due to the flexibility of the complex and reduce the degree of 
freedom, the solvent molecules are often removed to allow for a more effective search for the 
pose. Approaches to estimate or approximate the pose include the already mentioned rigid-body 
approximation, which treats both the protein and the ligand as rigid bodies. This approach only 
considers the 6 degrees of translational and rotational freedom and discards flexibility of the 
system [102]. A more commonly used, and preferable approach considers the ligand flexibility 
and models the protein as a rigid body [103] although there are systems that consider protein 
flexibility [94], receptor backbone flexibility is still a problem [99]. 
3.3.1. The flexible ligand-search docking algorithm uses three types of algorithms; 
1. Systematic docking algorithms 
In these algorithms all the degrees of freedom in a molecule are explored using conformational 
search methods (exploring all rotatable bonds of the ligand), fragmentation search methods ( 
assembling the ligand in the active pocket), and database search methods (docking pre-generated 
conformations in to the active pocket) [94], [99].  
2. Random or stochastic algorithms 
When using the random or stochastic algorithm, different conformations of the ligand or ligands 
are explored in the binding site and then accepted or rejected using a pre-defined probability. 
Three of the methods available for this approach are Monte Carlo method (MC) which is used 
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by Prodock, ICM, MCDOCK, DockVision and QXP, Genetic Algorithm method (GA) used by 
GOLD, AutoDock [92], [104], DIVALI and DARWIN and finally the Tabu search method used 
by PRO_LEADS program [94], [99].  
3. Simulation methods 
Simulation methods are based on calculating solutions to Newton’s equation of motion. 
Molecular dynamics (MD) and pure energy minimisation method use this approach. Examples 
of programs that use this method  are Prodock, ICM, QXP, DARWIN, DOCK 4.0 [105], ADAM 
and Hammerhead [94], [99] 
3.3.2. Flexible Protein Docking Algorithm 
Development of computational approaches that are able to account for protein flexibility during 
docking is still relatively new. To simulate docking in a fully flexible protein target within 
reasonable time is not yet computationally feasible. MD and MC approaches that can account 
for partial flexibility in the protein are available. Other approaches include rotamer libraries, 
protein ensemble grids and soft-receptor modelling [94], [99]. 
3.4. Scoring functions 
To be able to rank and score the ligand conformation is very important when docking because 
correct poses have to be delineated from incorrect poses [99]. In addition to generating the 
correct conformation, it is important that it is recognized as such and that it is distinguished from 
other alternatives. 
Due to the high computational expense that may be involved in scoring functions, analysis of 
several binding modes is made feasible by simplifying the scoring function, and as such their 
accuracy is reduced. In protein-ligand docking, scoring functions that are used are able to 
predict binding free energies. The three classes of scoring functions used in protein-ligand 
docking are:  
1. Force Field-Based Scoring 
Force field-based scoring functions calculate the sum of the protein and ligand interaction 
energy and the internal energy of the ligand. The D-Score, G-Score (Tripos force field), 
GoldScore and the AutoDock 3.0 scoring function (Amber force field) are force field based 
scoring functions [94], [99]. 
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2. Empirical Scoring Functions 
Empirical scoring functions make approximations by using both experimentally determined 
binding energies and training sets of protein-ligand crystals complexes to determine the binding 
energy. Examples include the Böhm’s scoring function, F-Score, ChemScore, SCORE, Fresno 
and X-SCORE [94], [99].  
3. Knowledge based Scoring Functions 
The third scoring functions are knowledge based and they use protein-ligand crystal structures 
and follow statistical rules and principles to derive their terms. Examples of knowledge-based 
scoring functions include Muegges’s Potential of mean force (PMF), DrugScore, and SMoG 
score [94].  
4. Consensus Scoring 
These scoring functions combine data form different scoring functions to reduce errors that arise 
from using individual scoring functions. Examples include X-CSCORE, which combines the 
PMF, ChemScore, and FlexX scoring functions with DOCK-like and GOLD-like algorithms 
[94], [99].                                                                  . 
 
3.5. Capabilities and limitations of docking 
Although most docking programs can predict the orientation of a known protein-ligand complex 
with an average of 1.5-2.0 Ǻ and a reported success rate of up to 80%, docking is still far from 
perfect. Major limitations arises from the imperfections of the scoring functions since, as 
previously mentioned, a lot of simplifications have to be made to make scoring functions 
computationally efficient in determining binding free energies or ligand affinity. Other factors 
that affect the quality of docking include the effect of the solvent and water molecules in 
protein-ligand interactions, the protein flexibility and the resolution of experimentally 
determined structures [94]. 
3.6.  Docking programs 
There are several molecular docking tools available and they use different approaches. The most 
popular docking programs are AutoDock, GOLD and FleX [94], [99]. For this project 
AutoDock4 and AutoDock Vina were used at different stages of the docking protocol. 
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3.6.1. AutoDock4 
Autodock4 is an automated docking tool that is part of a suit of programs that includes 
AutoDock, AutoGrid and AutoDock Tools (ADT). It combines an empirical free energy force 
field with a Lamarckian Genetic Algorithm to predict a protein-ligand conformation (pose) and 
its free binding energy. AutoDock4 also has a simulated annealing search method and a 
traditional genetic search method. AutoDock uses a grid-based method to search through the 
conformational space available to a ligand. This method makes it possible to rapidly predict the 
binding energy of the proposed pose. The scoring function of AutoDock has been calibrated 
using a set of 188 different protein-ligand complexes of known structure and binding energy. 
The inputs and outputs are pdbqt files that are prepared using ADT graphically or in batch 
mode. AutoDock4 also allows for flexible docking of specific parts of the protein and the ligand. 
Docking results can be clustered, displayed and analysed using different available methods[94], 
[104].  
AutoDock4 and ADT are currently being distributed free of charge at WWW sites: 
http://autodock.scripps.edu and http://mgltools.scripps/edu/downloads respectively. 
3.6.2. AutoDock Vina 
AutoDock Vina is an open source program for molecular docking. It was developed at the 
Molecular Graphics Lab at The Scripps Research Institute. The performance of AutoDock Vina 
has been tested on a set of 190 protein-ligand complexes that were used as a training set for 
AutoDock 4.0.1 and a twofold improvement in speed and better accuracy in predicting binding 
mode were observed during a comparison with AutoDock 4.0.1. AutoDock Vina requires a 
specification of the search area in which various ligand poses will be considered in the receptor. 
This can be accomplished by starting with a protein-ligand crystal structure complex and then 
creating an appropriate search space that includes the ligand binding site. There is no need to 
calculate grid maps and to assign atom charges. It uses multithreading to speed up execution by 
making use of multiple CPUs or CPU cores. AutoDock Vina uses the same pdbqt molecular 
structure file format used by AutoDock. The pdbqt files used in Autodock Vina  can therefore 
also  be generated in batch mode or in AutoDock Tools and be viewed using MGL tools [95].  
3.7. Anti-parasitic natural compounds 
Screening natural compounds provides an opportunity to discover unique molecules with 
properties that can be optimized by synthetic procedures. Examples include artemisinin, quinine 
and licochalcone A which are derived from plants, as well as antiparasitic products like 
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amphothericin B and ivermectin which were isolated from Streptomyces [106]. Several 
phytochemicals have been investigated for their activity against trypanosomes [107]. 
Natural compounds with anti-parasitic properties are diverse. Those that have been identified as 
potential drug leads and undergone in vivo and toxicity studies include quinoline alkaloids with 
anti plasmodial and anti-leishmania activity, bisbenzyl-isoquinolines with antiprotozoal activity, 
benzyl- and napththyl-isoquinoline alkanoids and indole alkaloids[106]. Terpenes that can be of 
value to drug development include sesquiterpenes like artemisinin which is active against the 
malaria protozoa, diterpenes like axisonitrile which is active against plasmodium, and limonoids 
like nimbolide which is active against plasmodia. Phenolics like lignans which include a group 
of natural products that have been shown to have activity against Trypanosoma cruzi  and can 
prevent transmission of T. cruzi by blood transfusion  [106] have also been identified.  
Although some natural products are disadvantaged by their high cytotoxicity and low 
therapeutic selectivity, they are still a good source of compounds that can be developed to form 
potent and viable drugs. Comparative molecular docking studies have been carried out on anti-
trypanosomal natural products into different T. brucei drug targets [108]. In this study the South 
African natural compounds database (SANCDB) [49] will be used as a source of compounds 
that will be screened for their anti-trypanosomal activity. 
3.8. Methods and materials 
In chapter two (Homology modelling and protein structure analysis), crystal structures of 
Trypanosoma brucei cathepsisn B (TbCatB), PDB ID: 3HHI and human cathepsin B (HsCatB), 
PDB ID: 3CBJ were used as templates to calculate homology models for, Trypanosoma 
congolense cathepsin B (TcCatB), Trypanosoma cruzei cathepsin B (TcrCatB) and 
Trypanosoma vivax cathepsin B (TvCatB) cysteine proteases. Since the crystal structure of PDB 
ID: 3CBJ was crystallized as an inactive protein with mutations (C29A, H110A, S115A) it 
could not be used for docking studies. Another HsCatB crystal structure (PDB ID: 1GMY) was 
retrieved from the NCBI database using the 3CBJ sequence as a query in a BLASTP search. The 
1GMY structure was crystalized at a resolution of 1.90Å, an R-value of 0.161% and R-free of 
0.199%. The ensemble coordinates of this structure were used for building the homology model 
that was used for making the TbCatB crystal structure [23].  
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Figure 3.0: An overview of the methods used for molecular docking studies. The crystal 
structures of TbCatB and HsCatB, calculated homology models, as well as compounds from the 
SANCDB were used. 
 
Superimposition of these two structures (1GMY and 3HHI) (Figure 3.1) showed the RMSD 
between the two structures is 0.601Å. These structures and the homology models were also used 
with compounds from the SANCDB in docking studies to identify leads for molecular dynamics 
and drug development. Figure 3.0 show an overview of the steps taken during docking studies.   
3.8.1. Data preparation for molecular docking   
Homology models of TcCatB, TcrCatB, TvCatB proteases were calculated using MODELLER 
version 9.10 (see chapter 2). The crystal structure of (TbCatB) in complex with a cysteine 
protease inhibitor (CA074) was retrieved from the protein data bank (PDB ID: 3HHI). The 
crystal structure of HsCatB (PDB ID: 1GMY) cathepsin B protease in complex with dipeptidyl 
nitrile inhibitor was retrieved from the NCBI database. The protein receptors were prepared by 
removing crystallographic waters and other bound heteroatoms using Accelrys Discovery Studio 
4.1 (Accelrys Software Inc. Discovery Studio Modelling Environment (DS), 4.1, San Diego: 
Accelrys Software Inc. 2014). This software was also used to separate the CA074 and the 
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dipeptidyl nitrile ligands from the 3HHI and the 1GMY proteases respectively. These inhibitors 
were used together with the protease structures to validate the docking method and to determine 
important interacting residues between the receptors and the respective ligands. Before docking 
validation, the protein receptors were all aligned in PyMOL [83] and the saved molecules were 
used for docking studies. The xyz coordinates of the central C-alpha of the active Cys residue of 
the aligned receptors were determined in DS for the grid centre. A total of 11 receptors were 
used in docking studies. These were HsCatB (1GMY), TbCatB (3HHI), Tc3CBJ, Tcr3CBJ, 
Tv3CBJ, and Tc3HHI, Tcr3HHI, Tv3HHI (Trypanosoma congolense, Trypanosoma cruzi and 
Trypanosoma vizax cathepsin B homology models calculated using PDB ID 3CBJ and 3HHI 
template coordinates respectively). Three more receptors used were TcCatB, TcrCatB and 
TvCatB (Trypanosoma congolense, Trypanosoma cruzi and Trypanosoma vizax cathepsin B 
homology models calculated using a combination of both PDB ID 3HHI and 3CBJ template 
coordinates).  
3.8.2. Docking validation in Autodock4 
Autodock tools were used for preparation of pdbqt files of the ligand and proteins. The search 
area was also determined using AutoDock4. The two ligands were then re-docked in to their 
respective receptors in an attempt to reproduce the original poses. 
3.8.2.1.  Ligand and protein protonation 
Docking algorithms require atoms to have a charge and atom type, since the PDB structures and 
the model structures do not have these. The protein structures and the ligands were converted 
into (pdbqt) conformations using AutoDock Tools (ADT). To do this, polar hydrogens were 
added to the protein receptors and non-polar hydrogens merged. Gasteiger charges were then 
calculated followed by assigning AutoDock4.2 (ADT4) atom types. Torsions were 
automatically assigned to the ligands. Python scrips provided by ADT together with customised 
python scripts were used (Appendix 2A-1&2). 
3.8.2.2.  Vina configuration file preparation 
To select the search space for the active site pose, for each protein-ligand complex the 
experimentally bound ligand structures were used as starting points from which to determine the 
centre and search area size for each of the aligned receptors. The centre for the aligned receptors 
was set on the central C-alpha of the active Cys residue. The xyz coordinates for this centre 
were respectively set to -16.67, -17.76 and 17.76. The grid size was adjusted to a final size of   x 
= 30.00Å, y = 31.875Å and z = 31.875Å. This was done to make sure that the size of the search 
space is large enough to allow the ligand to rotate as recommended by the developers of 
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AutoDock [95] and to give allowance for large compounds that will be screened from the 
SANCDB.  
3.8.3. Docking validation and HTS in AutoDock Vina 
The two ligands were re-docked into the corresponding receptors using AutoDock Vina, (using 
parameters to be used with screening the SANCDB). The Vina configuration file was prepared 
by setting the centre and grid size as explained for docking parameter file preparation (section 
3.7.2.2 above). A script was used to create new files with “.vina” extension for possible ligand-
protein complexes during HTS of SANCDB (Appendix 2A-1). The vina parameter files 
contained the absolute path to the ligand(s) and proteins. The script also generated job files per 
ligand in SANCDB. An OpenPBS command, qsub, was used to schedule the job scripts to be 
executed by the cluster during HTS. After completion of docking, the lowest docking energy 
was extracted from vina output all.pdbqt file using another script. To speed up the running time, 
a total of 4 CPUs were used simultaneously for each docking experiment. The extent of 
searching for the global minimum (exhaustiveness) and the energy range were also set to 4 in 
the vina docking parameter file. Results were analysed in DS, Excel and in PyMOL. 
Docking method Energy range  Exhaustiveness Cpu usage 
AutoDock Vina 
active site docking 
4 4 4 
Table 3.2: Docking parameters used in active site docking in AutoDock Vina.  
3.8.4. Results and discussion 
PyMOL was used to visualise the molecules and prepare the figures from the experiments. 
3.8.4.1.  Data preparation for molecular docking 
Figure 3.1(A) shows the crystal structure of HsCatB (1GMY) superimposed to that of TbCatB 
(3HHI). The two structures are in-complex with their ligands which are coloured in similar 
colours to the receptors. The active site Cys122(29), (TbCatB numbering with HsCatB in 
brackets), is shown in red. The RMSD of the two structures is 0.601Å. The occluding loop of 
the two structures is open to the same extent. In the superimposition of the two structures in 
Figure 3.1(B), the CA074 inhibitor (yellow) is bound along the active site cleft of TbCatB by 
non-covalent interactions which are dominated by hydrogen bonds [23]. The dipeptidyl nitrile 
inhibitor (green) is covalently bound to the active site cysteine residue in HsCatB [109].  
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Figure 3.1: Showing (A) HsCatB (green) and TbCatB (yellow) superimposed crystal structures. 
Active site Cys122(29) is shown in red. RMDS = 0.601Å.  
 
Figure 3.2 shows all the protease receptors superimposed. The main observable difference 
between these structures can be seen in the occluding loop of the structures. The occluding loop 
of Tc3CBJ, Tcr3CBJ and Tv3CBJ models is open wider than that of the other proteases. This 
orientation is inherited from the 3CBJ template which was crystalized in-complex with a large 
chagasin cysteine protease inhibitor.  In this orientation, these proteases are likely to 
accommodate larger compounds and allow compounds to go deeper into the active site cleft 
than the rest of the proteases 
 
Figure 3.2: Superimposed structures used for docking experiments. The occluding loop of 
models Tc3CBJ, Tcr3CBJ and Tv3CBJ is open wider than that in other receptors.  
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The occluding loop of cathepsin B protease is a unique feature that gives it its carboxypeptidase 
activity under certain pH conditions. It can adopt multiple conformations and when it is in the 
closed conformation (at low pH) it blocks the primed site of the active site and restricts access of 
two residues (H110 & H111). When in this conformation the H110e residue forms a salt bridge 
with Asp22e thus holding the occluding loop in place. When the pH is raised, the salt bridge is 
broken when the H110e becomes deprotonated. This allows the occluding loop to move and 
open access to the H111e which provides a positive charge to hold the C-terminal carboxylate of 
a substrate during carboxypeptidase activity [37].  
3.8.4.2.  Docking validation results 
The results for docking validation of the CA074 cysteine protease inhibitor indicate that the 
validation was successful (Figure 3.3). In the original crystal structure complex, 3HHI, 
hydrogen bonds between the inhibitor and the receptor are more dominant than hydrophobic 
interactions and the phenylsulphone moiety is at the P1’ position [23].  
 
Figure 3.3: Showing the original position of the CA074 cysteine protease inhibitor (navy blue) 
and the docked pose (yellow) in TbCatB cystal structure. The active site Cys122 is marked red. 
 
Figure 3.4 (A) shows major interactions between the enzyme and the original inhibitor. The 
inhibitor forms hydrogen-bonds between an oxygen atom and a nitrogen atom of Gln116. It also 
forms a hydrogen-bond with a nitrogen atom of Cys122. This forms the oxyanion hole which 
stabilizes the tetrahedral intermediate which forms during substrate hydrolysis [21]. Another H-
bond interaction is formed between the terminal oxygen of the ligand and a nitrogen atom of 
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His194 and between an oxygen atom and a carbon atom of His282. The terminal oxygen also 
forms electrostatic interactions with Trp304. Hydrophobic interactions are also formed between 
the Val259 and a carbon atom of the ligand. In the re-docked inhibitor (Figure 3.4 B), the H-
bond between Gln116 and the ligand was formed with a different oxygen atom. The 
hydrophobic interaction between Val259 and the carbon atom was replicated. The carbon atom 
of the inhibitor forms two other hydrophobic interactions with His282 and His304 of the 
enzyme. The phenylsulphone moiety at the P1’ was correctly replicated. 
 
Figure 3.4: Showing (A) the original CA074 ligand and (B) docked ligand pose interactions with 
important residues in TbCatB (3HHI) protease.  
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Figure 3.5: Showing the original position of the dipeptidyl nitrile protease inhibitor (navy blue) 
and the docked pose (yellow) in HsCatB cystal structure. The active site Cys29 is marked red. 
 
The orientation of the original and the docked dipeptidyl nitrile inhibitor in HsCatB is shown in 
Figure 3.5. The original inhibitor was covalently bonded to the enzyme to the active Cys29 
residue    by a thioimidate ester bond  [109] and hydrogen bond interactions between the 
backbone NH of Cys29 and the side chain amide of Gln23 stabilized the intermediate. In Figure 
3.6 (A) it is observed that there is a hydrogen bond interaction between the side chain amide of 
Gln23 and the terminal nitrogen of the ligand. However this interaction is not replicated in the 
docked pose (Figure 3.6 B). This is due at least in part to the inability of docking to replicate the 
covalent bond between the inhibitor and the Cys29. However the hydrophobic interaction 
between Tyr75 and the phenyl ring of the ligand was replicated. A hydrophobic interaction 
between Pro76 and another phenyl ring of the ligand was also replicated. 
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Figure 3.6 Showing (A) the original dipeptidyl nitrile ligand and (B) docked ligand pose 
interactions with important residues in HsCatB (1GMY).  
 
3.8.4.3.  Docking validation conclusions 
Although not all the original ligand and protein interactions could be replicated for both 3HHI 
and 1GMY complexes, the docked ligand in both cases adopted the original ligand position and 
replicated enough interactions for the validation to be concluded as successful. The parameters 
that were used for docking validation were deemed reliable for use in HTS of South African 
natural compounds. 
3.8.5. Screening of South African natural compounds in Autodock Vina 
A total of 600 natural compounds of South African origin were retrieved from the South African 
natural compounds database (SANCDB)[49], https://sancdb.rubi.ru.ac.za. All of these 
compounds were screened into all the protease structures without regard for their anti-parasitic 
or lack of anti-parasitic properties. The main aim was to obtain lead compounds that have 
potential use in drug development against TbCatB protease.  
The SANCDB is the first web-based natural products (NP) database in Africa. It contains 
compound information for NPs extracted from different referenced sources like journals, books 
and theses. The database is curated and it allows researchers to submit entries. The aim of the 
database is to provide researchers with natural compounds of South African origin that can be 
used for virtual screening in drug discovery. The compounds were isolated from plants and 
marine organisms. Information provided about the compounds include the use of a given 
compound; e.g. anticancer and the organism from which it was extracted. The compounds can 
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be downloaded in Mol2, PDB, SDF and SMILES formats [49]. Access to the database is free 
and it is available at https://sancdb.rubi.ru.ac.za/.  
3.8.6. Docking analysis  
Python scripts were used to prepare the compounds and the receptors for docking by generating 
the pdbqt files. Scripts were also used for automating the writing of vina parameter files and for 
running of the jobs. AutoDock Vina was used for HTS of compounds because of its accuracy 
and the advantage of using multiple cores of CPU simultaneously. HTS of compounds was 
carried out in a heterogeneous Linux cluster running CentOs 5.8 with OpenPBS Batch queue 
system. The cluster is composed of 1 Dual Intel Xeon CPU ES-2620 (2 GHz) (12 cores), 1 Dual 
AMD Opteron 6344 (2,6 GHz) (24 cores) and 9 Dual Intel Xeon PU E5520 (2,2 GHz) (8 cores). The 
server has 108 processors, out of which 96 cores are available for use.  A python script was used to 
extract docking energies from the vina output “all.pdbqt” file. Microsoft Excel 2010 and R-
studio were used in analysis of the docking energies. 
3.8.7. HTS Results and discussion 
A total of 600 compounds from the SANCDB were docked into all the protein receptors using 
AutoDock Vina. Lead compounds were selected based on their selectivity to TbCatB and on 
their potential to inhibit all the Trypanosomal cathepsin B proteases but not the human cathepsin 
B protease. Based on binding (docking) energies, compounds with a docking energy of more 
than 1kcal/mol improvement when bound to TbCatB than to HsCatB where selected to be more 
specific to TbCatB. To determine this, the average docking energy of each compound across the 
set of Trypanosomal cathepsin B proteases was calculated and then the difference between this 
average docking energy and the docking energy in HsCatB for that particular compound was 
calculated. Selected compounds were further analysed in Discovery Studio analyser. From this 
analysis, only compounds that docked into the active site pocket of TbCatB and that of other 
Trypanosomal cathepsin B proteases were selected as lead compounds. A total of nine 
compounds, SANC00 478, 479, 480, 481, 482, 488, 489, 490 and 491were selected. Table 3.3 
and Figure 3.7 show a list of the leads compounds and their docking energies in all the protease 
receptors.  
 
Receptors Tc3CBJ, Tc3HHI and TcCatB are all homology models of Trypanosoma congolense 
Cathepsin B protease made from different templates (PDB ID: 3CBJ and PDB ID: 3HHI) and a 
combination of those templates. All selected lead compounds bound more strongly to the 
Tc3CBJ homology model than to the Tc3HHI and TcCatB models (except SANC00488 which 
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bound more strongly to Tc3HHI). This could be because the occluding loop in Tc3CBJ is more 
open than those in the other two (Tc3HHI and TcCatB) proteases and so it allows access to more 
interacting residues deeper in the active pocket. The same observation is made when comparing 
Trypanosoma vivax cathepsin B homology models (Tv3CBJ, Tv3HHI & TvCatB), all the 
compounds bound more strongly to Tv3CBJ model than to Tv3HHI and TvCatB models (except 
SANC 00489 which has an equal binding energy in both Tv3CBJ and TvCatB).  
 
Table 3.3: Showing the binding energies of leads compounds in all the receptors. All the leads 
compounds bind more strongly to Trypanosome spp. catBs than to human cathepsin B. 
 
Figure 3.7: Showing the binding energies of the lead compounds in all the receptors. All the 
leads compounds bind more strongly to trypanosome ssp. catBs than to HsCatB. 
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Figure 3.8: Showing the estimated binding energies of the lead compounds in all the receptors. 
The energy scores are colored from lowest energy/ strongest binding (white) to highest energy/ 
weakest binding (red). All the lead compounds bind more strongly to Tripanosomal catBs than 
to HsCatB.  
 
However a comparison of the Trypanosoma cruzi cathepsin B models show that only two 
compounds (SANC00 490 & 491) bound more strongly to the Tcr3CBJ (more open colluding 
loop) than to Tcr3HHI and TcrCatB. 
The heat map in Figure 3.8 also shows that the compounds have less affinity for HsCatB and 
more affinity for Trypanosomal cathepsin B proteases, with stronger affinity for Tc3CBJ and 
Tv3CBJ. 
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Structures 3HHI template 3CBJ template 3HHI_3CBJ template 
TcCatB - 1.12 - 0.90 - 1.01 
TcrCatB - 0.59 - 0.30 - 0.55 
TvCatB - 1.20 - 1.10 - 1. 39 
Table 3.4: Listed are the DOPE Z-scores of the models. The DOPE Z-scores of the templates 
were – 1.44 and – 1.14 for 3CBJ and 3HHI respectively. 
Structures 3HHI template 3CBJ template 3HHI_3CBJ template 
TcCatB 0.173 0.240 0.281_0.536 
TcrCatB 0.262 0.312 0.303_0.537 
TvCatB 0.196 0.251 0.262_0.578 
Table 3.5: Listed are the RMSD values showing the similarity between the homology models 
and the templates. The RMSD of the templates was found to be 0.668.  
3.8.7.1.  Selection of homology models for MD simulation 
The remainder of this study concentrates on only one homology model of each of the 
Trypanosoma congolense cathepsin B, Trypanosoma cruzi cathepsin B, and Trypanosoma vivax 
cathepsin B. The models were selected based on their DOPE Z scores and RMSD scores (Tables 
3.4 and 3.5). The selected models were calculated from the 3HHI template and were assigned 
the following abbreviations: Trypanosoma congolense cathepsin B (TcCatB), Trypanosoma 
cruzi cathepsin B (TcrCatB), and Trypanosoma vivax cathepsin B (TvCatB). 
3.8.7.2.  Lead compounds and receptor complexes 
Figure 3.9 shows the docking pose and docking energies of SANC00478 in the protease 
receptors. The strongest binding energy of  -10.3 kcal/mol in (Figure 3.9 B) is with TbCatB, 
while the weakest binding energy of -9.0 kcal/mol is with HsCatB protease. This is a difference 
of 1.03 kcal/mol in binding between the two proteases which indicates that the compound has a 
strong preference to bind to the active site of TbCatB than to HsCatB. It also binds more 
strongly to TcCatB, TcrCatB and TvCatB than to HsCatB.  
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Figure 3.9: SANC00478 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
The binding of SANC00478 is along the active site cleft in all the receptors. This compound is 
listed in the SANCDB as cephalostatin 2 and a previously known property is its anticancer 
activity. For more information see Appendix 1A-1. 
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Figure 3.10: SANC00479 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
SANC00479 pose and docking energies in the receptors are shown in Figure 3.10.  This 
compound has a docking energy of  -10.6 kcal/mol when bound to TbCatB and -7.7 kcal/mol 
when bound to HsCatB. This compound is selective for TbCatB with a docking energy 
difference of  2.9 kcal/mol between average binding to Tripanosomal and Human cathepsin B’s. 
SANC00479 also prefers to bind along the active site cleft, except in TcCatB (Figure 3.10 C) 
where it is bound towards the occluding loop. It also binds strongly to all the Trypanosomal 
cathepsin B proteases than to HsCatB. This compound is also listed in the SANCDB as 
cephalostatin 3 and also has known anticancer properties. For more information see Appendix 
1A-1. 
In Figure 3.11 similarly illustrate the docking pose and docking energies of SANC00480. The 
strongest docking energy of -10.2 kcal/mol for this compound is with TbCatB while the weakest 
is -8.6 kcal/mol when it is bound to HsCatB, and there is a preference for binding along the 
active site cleft in all the proteases. It also has a stronger binding energy to bind to TbCatB and 
other Trypanosomal cathepsin B proteases than to HsCatB. This compound is listed in the 
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SANCDB as cephalostatin 4 and it again, like many of the cephalostatins exhibits anticancer 
activity. For more information see Appendix 1A-1. 
 
Figure 3.11 SANC00480 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
SANC00481 binds along the active site cleft in all the proteases as shown in Figure 3.12. It also 
binds more strongly to Trypanosomal cathepsin B proteases than it does to HsCatB. The 
docking energy of this compound in TbCatB is -10.4 kcal/mol and -8.0 kcal/mol in HsCatB. A 
docking energy difference of 2.4 kcal/mol shows that the compound is selective for TbCatB. 
Again, this is a cephalostatin, cephalostatin 7 with typical anticancer propetties. For more 
information see Appendix 1A-1. 
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Figure 3.12 SANC00481 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
SANC00482 binds similarly with these cathepsin B proteases (Figure 3.13), however with less 
affinity for binding to HsCatB compared to the rest of the proteases. This compound also shows 
potential to be specific for TbCatB. Its Docking energy is -10.2 kcal/mol in TbCatB and -8.4 in 
HsCatB. This compound is listed in the SANCDB as cephalostatin 8. For more information see 
Appendix 1A-1. 
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Figure 3.13 SANC00482 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
The docking poses and docking energies of SANC00488 can be seen in Figure 3.14.  The 
compound binds along the active side of all the Trypanosomal cathepsin B proteases but does 
not bind along the active site of HsCatB.  The binding energy of this compound when it is bound 
to HsCatB is -7.7 kcal/mol, which is one of the weakest binding of all the leads compounds. 
SANC00488 shows a different pattern of binding compared to the previously discussed 
compounds among the Trypanosomal cathepsin B proteases. It binds to TcrCatB (Figure 3.14 D) 
with a binding energy of -9.5 kcal/mol and the strongest is when it is bound to TcCatB with a 
docking energy of -10.7 kcal/mol. The binding to TcCatB and TbCatB is also good.  This shows 
that the compound has marked preference for binding to the Trypanosomal cathepsin B 
proteases and it also has a potential to act as a broad spectrum inhibitor of the current set of 
Trypanosomal cathepsin B proteases. This matches the observed geometries of binding where it 
appears as though SANC00488 is unable to fit within the cleft of HsCatB which also has a much 
lower binding affinity. Based on these observations, these complexes (Figure 3.14) shall be 
analysed further to determine protein residues that interact with the compound. Further analysis 
of these complexes shall be carried out using molecular dynamics. SANC00488 is listed as 
cephalostatin 14 in the SANCDB. More information on this compound is in appendix 1A-2. 
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Figure 3.14 SANC00488 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
SANC00489 also shows potential to be used as a broad spectrum inhibitor (Figure 3.15).  This 
compound prefers to bind along the active site cleft of the cathepsin B proteases, (and also 
HsCatB, although with poorer binding affinity), except for TcCatB protease (Figure 3.15 C) 
where is prefers to bind to a position closer to the occluding loop. SANC00489 is cephalostatin 
15. Appendix 1A-2 has more information on the compound.  
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Figure 3.15 SANC00489 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
SANC00490 (cephalostatin 16) and SANC00491 (cephalostatin 17) show an interesting 
variation in binding along the active site of cathepsin B proteases. In TcCatB, for instance 
SANC00490 is bound towards the occluding loop position. The docking energies also show that 
these compounds have strong affinity for Trypanosomal cathepsin B proteases rather than for 
HsCatB (Figure 3.16 and Figure 3.17). More information can be found in appendix 1A-2 
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Figure 3.16 SANC00490 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
Figure 3.18 shows a closer look at the binding energies of SANC00488 in TbCatB, TcCatB, 
TcrCatB, TvCatB and HsCatB. The compound clearly has less affinity to HsCatB than to the 
other proteases. A closer look at the interactions between this compound and protein residues 
will reveal the contributing factors to this bindings. In Figures 3.18 to 3.23, we look at the 
important residues that interact with SANC00488 in our protein receptors. 
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Figure 3.17 SANC00491 pose (navy blue) in (A) HsCatB (1GMY), (B) TbCatB (3HHI), (C) 
TcCatB, (D) TcrCatB, and (E) TvCatB. Docking energies (kcal/mol) are written below each 
complex. The active site Cys residue is marked in red. 
 
SANC00488 interacts with HsCatB by forming hydrophobic and hydrogen bonds with S2 
subsite residues. The compound forms a π-alkyl hydrophobic bond of 4.36Ǻ with Pro76 in the 
S2 subsite. Another alky hydrophobic interaction of 3.53Ǻ is formed between the compound and 
Ala173. Two hydrogen bonds which are 2.71Ǻ and 2.84Ǻ long are formed between the 
compound and Glu245 and Asn72 residues respectively. Interaction with the S2 subsite 
residues, especially Glu245 presents an opportunity to design derivatives of this compound with 
even less affinity for HsCatB. The S2 subsite determines specificity of this protease and it 
differs with TbCatB at the bottom of the S2 subsite where the Glu245 residue is substituted for 
Gly328. 
SANC00488 interacts with Phe208, Ala118, Cys162, Asn163 and Ala256 residues in TbCatB. 
Interaction with the Phe208 residue is by formation of a hydrogen bond of 1.87Ǻ. Another 
hydrogen bond of 1.98Ǻ is formed between the compound and Asn163 residue. The Ala118 
residue forms both an alkyl hydrophobic bond of 3.68Ǻ and a hydrogen bond of 2.78Ǻ with the 
compound. The Cys162 and Ala256 form alkyl hydrophobic interactions of respectively 4.73Ǻ 
and 4.12Ǻ with the compound.  The compound forms three hydrogen bonds with TbCatB as 
opposed to only two formed with HsCatB. Two of the H-bonds formed between SANC00488 
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with TbCatB are also shorter than those it formed with HsCatB. These differences contributed to 
the compound having a stronger affinity for TbCatB than to HsCatB.   
 
Figure 3.18: Showing SANC00488 interactions with important residues in HsCatB (1GMY). 
Bond interactions are colour coded; hydrophobic interactions (light purple), electrostatic 
interactions (brown), non-classical H-bonds (light grey), classical H-bonds (green). 
                             
Figure 3.19 Showing SANC00488 interactions with important residues in TbCatB (3HHI). 
Bond interactions are colour coded; hydrophobic interactions (light purple), electrostatic 
interactions (brown), non-classical H-bonds (light grey), classical H-bonds (green). 
Two hydrogen bonds and alkyl hydrophobic interactions are formed between SANC00488 and 
TcCatB protease (Figure 3.20). The hydrogen bonds which are respectively 2.10Ǻ and 3.08Ǻ 
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long are formed between the compound and Tyr134 and Lys90 residues. Hydrophobic 
interactions are formed between interactions with Ala45 and Cys89. 
Bonding between SANC00488 and TcrCatB is stabilized by hydrogen bonds between the 
compound and Gly181, Ser21, Cys65 and Tyr69 residues. Hydrophobic interactions between the 
compound and His89, Cys107, and Tyr69 residues also contribute to stability of the complex 
(Figure 2.21). 
 
Figure 3.20 Showing SANC00488 interactions with important residues in TcCatB. Bond 
interactions are colour coded; hydrophobic interactions (light purple), electrostatic interactions 
(brown), non-classical H-bonds (light grey), classical H-bonds (green). 
In TvCatB, the docked SANC00488 forms hydrophobic interactions with His131, Tyr89, Pro90 
and Ala178. Only one hydrogen bond is formed between the compound and Gln250 residue 
(Figure 3.22). 
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Figure 3.21: Showing SANC00488 interactions with important residues in TcrCatB. Bond 
interactions are colour coded; hydrophobic interactions (light purple), electrostatic interactions 
(brown), non-classical H-bonds (light grey), classical H-bonds (green). 
 
Figure 3.22: Showing SANC00488 interactions with important residues in TvCatB. Bond 
interactions are colour coded; hydrophobic interactions (light purple), electrostatic interactions 
(brown), non-classical H-bonds (light grey), classical H-bonds (green). 
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3.9. Conclusion 
Six hundred natural compounds of South African origin were screened into HsCatB, TbCatB, 
TcCatB, TcrCatB and TvCatB proteases using AutoDock Vina. The compounds SANC00 478, 
479, 480, 481, 482, 488, 489, 490 and 491were selected as potential leads for drug development 
based on their strong affinity for Trypanosomal spp. cathepsin B proteases. These natural 
compounds, which are all cephalostatins, have a higher affinity for binding to Trypanocidal 
cathepsin B proteases than to HsCatB. SANC00488 has the highest affinity for Trypanocidal 
cathepsin B proteases and the lowest affinity for HsCatB. 
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Chapter 4.       
4.1. Molecular dynamics simulation 
In chapter 3, 600 compounds were screened from the South African Natural Compounds 
Database (SANCDB) into Human cathepsin B (HsCatB), Trypanosoma brucei cathepsin B 
(TbCatB), Trypanosoma congolense cathepsin B (TbCatB), Trypanosoma cruzi cathepsin 
B(TbCatB),  and Trypanosoma vivax  cathepsin B(TbCatB)  proteases. A total of nine lead 
compounds were selected for displaying more affinity to inhibit Trypanosomal species cathepsin 
B proteases than HsCatB. This selection was based on the binding energy of the compounds to 
the proteases. SANC00488 was observed to show more affinity to Trypanosomal species 
cathepsin B proteases and less affinity to HsCatB than the other lead compounds. The 
complexes with the proteases were selected for further analysis using Molecular Dynamics 
(MD) simulations. Using Discovery Studio, ligand receptor interacting residues were 
determined for the complexes. MD simulations were carried out to understand the behaviour 
(conformational changes and fluctuations) of these interactions over time under conditions that 
are closer to physiological conditions.  
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4.2. Introduction 
Molecular dynamics simulations are used widely in the study of biological macromolecules 
[110]. Two rather similar techniques used for simulation are molecular dynamics (MD) and 
Monte Carlo (MC). Simply molecular dynamics (MD) is a computer simulation of the physical 
movements of atoms and molecules in the context of N-body simulation 
(https://en.wikipedia.org/wiki/Molecular_dynamics).  
MD was first introduced by Alder and Wainwright in the late 1950’s to study the interactions of 
hard spheres [111] and important insights related to the behaviour of simple liquids emerged 
from their studies. The first MD simulation of a realistic system was then carried out by Rahman 
and Stillinger in their simulation of liquid water in 1974. The first protein MD simulation which 
was carried out on a protease (bovine trypsin inhibitor) with just 58 residues and ~450 atoms 
was done for 8.8 psec in vacuo [112]. Increases in computer power over the years has allowed 
for simulation of large systems containing 10
4
-10
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 atoms. Improvements in force fields, 
treatment of long electrostatic interactions and system boundary conditions, and better 
algorithms for temperature and pressure control make it possible to make simulations of more 
realistic systems that include explicit water molecules, counter ions and membrane like 
environments. Although parameters for protein interaction are found in modern force fields, the 
parameter for ligands are often not adequately represented in these sets.  
MD simulations are carried out to gain information about the properties of the way molecules 
are assembled in relation to their structure and their microscopic interactions [113]. MD 
simulations are important to understand fluctuations and behaviour of interactions between 
biological molecules and to show their conformational changes over time [110]. Biological 
systems are complex; so computer methods have become important in life sciences since MD 
simulations make it possible to study the effect of explicit solvent molecules on protein structure 
and stability over a certain period of time [110]. As an example, MD simulations were used to 
examine conformational changes of GPR40 within the hydrated lipid environment [114]. The 
researchers used MD simulation to show that agonists can bind to the active site of GPR40 and 
that simulation may alter the original docked pose. They were able to identify residues that are 
critical for GPR40 and ligand binding. It is worthy to note that MD simulations are also used for 
refining X-ray or NMR structures [110]. 
In drug design, MD simulation can be combined with docking to predict more reliably stable 
protein-ligand complexes. Structures obtained after MD simulation are more representative of 
conformations available for binding with inhibitors in solution [115]. During the drug design 
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process, docking is used to screen large libraries of drug like compounds over a short period of 
time to reduce them to a reasonable number of hits. The lack of or poor flexibility of the protein 
during ligand binding and the absence of a scoring function that is universal make docking 
results incomplete on their own. Since during MD simulation both protein and ligand can be 
treated as flexible, the protein can change its conformation to the bound ligand and produce a 
more induced fit and accurate free energies of binding maybe calculated. During the simulation, 
incorrectly docked complexes produce an unstable trajectory while correct complexes produce a 
stable trajectory.  
4.3. MD simulation methods 
The two main families of MD simulation are molecular ‘classical’ mechanics and ‘quantum’ 
mechanics simulations.  
In the ‘quantum’ or ‘first-principles’ MD simulations the quantum nature of the chemical bond 
is taken into account. Although they are useful in providing information of biological systems, 
quantum MD simulations require more computational resources limiting their use to short 
simulations of very small systems. In particular, in order to simulate the progress in a simulation 
over the order of nanoseconds or to deal with biological macromolecules the use of a purely 
quantum approach is unfeasible. In these cases classical MD is most practical for simulations of 
biological systems for periods of nanoseconds [111].  
In molecular ‘classical’ mechanics simulation, molecules are treated as classical objects. Atoms 
represent soft balls and bonds represent elastic sticks in what is termed a force field. This 
system’s dynamics are defined by the laws of classical mechanics [111].  
4.3.1. Molecular ‘classical’ mechanics simulation steps 
Dynamics simulations are typically run in water where periodic boundary conditions and the 
size of the simulation box are set. In the case of proteins the systems is neutralised by adding 
ions or cations and then topologies are generated using an appropriate force field. The most 
commonly used force fields in MD simulation are AMBER, AMOEBA, CHARMM, NAMD 
and GROMOS force fields. The system is then minimised to relax the system to avoid having 
atoms forced out of the trajectory since forces in the system can result in displacement of some 
bonds. During minimisation the temperature of the system is lowered towards 0 K, so energy is 
added to the system to bring it to the operating temperature (heating). The system is then 
equilibrated to allow the structures to expand or contract.  After removal of artefacts, the system 
in ready for production dynamics. The dynamics of the system can then be observed after 
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running production dynamics for a period of time (ns). Analysis of trajectories can be carried 
out visually by using a molecule visualisation system like PyMOL or Visual Molecular 
Dynamics (VMD). Graphical representation of results can be plotted using Xmgrace of Grace 
5.1.21. If the trajectories have not stabilised it might be necessary to increase the time for 
production dynamics.  
Available MD simulations packages include (i) CHARMM which uses the CHARMM force 
fields (E/I; All Atom/United Atom), and Amber force fields, (ii) Amber which uses Amber (A/I 
; All Atom) force fields, (iii) GROMOS which uses Gromos (E / vacuum ; United Atom) force 
fields and NAMD package which uses CHARMM, Amber and Gromos force fields. 
4.4. GROMACS 4 package 
Gromacs is a free software package that is used to perform molecular dynamics for systems with 
up to millions of particles. It was designed for biological molecules like proteins, nucleic acid 
and lipids. It uses an interface with command line options for input and output files. Topologies 
and parameter files are written in text format. During simulation, you can monitor the progress 
of the simulation and it also tells you the expected finish time and date. To reduce the edge 
effect in the system, Gromacs uses the concept of periodic boundary condition. Simulations can 
be run in a triclinic, cubic and octahedral model boxes [112]. Gromacs may also be run in 
parallel using the standard MPI communication protocol or via the “Thread MPI” library for 
single node workstations. GROMACS 4 also uses dynamic load balancing to improve 
performance for protein simulations [116]. A selection of tools is provided for trajectory 
analysis and the output is in the form of finished Xmgr/Grace graphs with labelled axis and 
legends. It is developed by the GROMACS development team at, Uppsala University & The 
Royal Institute of Technology, Sweden. http://www.gromacs.org. 
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4.5. Methods and materials 
 
Figure 4.0: An overview of the methods used for MD studies. Complexes of SANC00488 with 
HsCatB, TbCatB, TcCatB, TcrCatB and TvCatB were used. 
4.5.1. Data preparation 
Docking and selection of complexes for MD simulation was carried out as described in chapter 
2. A total of nine compounds, SANC00 478, 479, 480, 481, 482, 488, 489, 490 and 491were 
selected as lead compounds based on their affinity for Trypanosomal spp. cathepsin B proteases. 
From this list SANC00488 was selected as the best lead. In this chapter MD simulations of 
SANC00488 in complex with Human cathepsin B (HsCatB), Trypanosoma brucei cathepsin B 
(TbCatB), Trypanosoma congolense cathepsin B (TcCatB), Trypanosoma cruzi cathepsin B 
(TcrCatB) and Trypanosoma vivax cathepsin B (TvCatB) were carried out to study the complex 
structures under conditions that resemble physiological conditions and to predict the binding 
mode of the compound in the structures. 
The complexes were opened in Discovery Studio Visualizer and polar hydrogens added and the 
protonation state of the proteins set to pH 5.0. Python scripts were then used to split the ligand-
receptor complex and save them in different files.  
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A python script was written and used to run ACPYPE interface and Open Babel to process 
ligand PDBs in to GROMACS format files (topology files).  
Another python script was used to process the protein and to combine the protein and ligand 
topology in preparation for solvation and boxing, energy minimisation, equilibration (NVT and 
NPT) and production run. This script was originally written within the research group [101], but 
was modified for these experiments. Production dynamics was carried out at the Centre for High 
Performance Computing (CHPC) using scripts that were available to the research group [101].  
MD simulations were performed using the GROMACS 4.5.7 package with the AMBER96 force 
field. The ligand-protein complex was solvated and neutralized in a triclinic box of 17.5 Å filled 
with generic equilibrated 3-point solvent water (spc216.gro). The complex was placed at least 3 
nm from the edge of the box. The whole system was neutralised by adding (0.15 M) Na
+
 and Cl
-
 
counter ions to replace water molecules. The energy of the complex was minimized to 1000 
kJ/mol/nm using the steepest descent approach of 100000 steps without constraint. The system 
was allowed to equilibrate at a constant temperature of 300K with each minimised ensemble 
system equilibrated in the canonical ensemble for 200 ps (nsteps = 100000), through the NVT 
ensemble and for 200ps in the isothermal-isobaric ensemble. The conditions for the NPT were 
set at 1.0 bar of pressure with a pressure coupling constant of 2.0 ps. To simulate water the 
isothermal compressibility values were set to 4.5 x 10
-5
 /bar. Simulation was set to run for 20 ns 
with an integration time step of 2 femtoseconds (fs) at constant temperature and pressure. The 
LINCS algorithm was used to constraint all bond lengths during equilibration and production. 
For neighbour searching, the cut off distance was set to 1.4 nm for Coulomb and van der Waals 
interactions. Electrostatic interactions were approximated by the Particle Mesh Ewald for long 
range electrostatics with a 0.16 nm Fourier grid spacing and a fourth order cubic interpolation. 
Trajectories were saved every 2 ps during simulation. The trajectories were analysed using 
Xmgrace of Grace 5.1.21 to plot the MD graphical displays. To visualise the trajectories, the 
Visual Molecular Dynamics (VMD) program version 1.9 was used.    
4.5.2. Results and discussion 
Comparison of simulation results with experimental results were carried out in reference to Root 
Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF). Cα atom RMSD 
comparisons were carried out relative to the energy minimised starting structure. RMSD 
analysis was carried out using xmgrace. Visual analysis of conformational changes was carried 
out using VMD. Although the system was set to simulate for 20 ns, the production MD was 
terminated after 14 ns due to the job control system at the CHPC (set to 100 hrs) before 
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completion of the simulation. Since the behaviour over 13 ns was deemed sufficient, our 
analyses are for a 13 ns simulation. 
Figure 4.1 shows the Cα atom RMSD of Human cathepsin B (HsCatB), T. brucei (TbCatB), T. 
congolense (TcCatB), T. cruzi (TcrCatB) and T.vivax (TvCatB) receptors in complex with 
SANC00488 (ligand) as a function of the simulation time (13 ns of the final molecular 
dynamics). 
 
Figure 4.1: Showing comparison of Cα atom RMSD (relative to the energy minimized starting 
structure) as a function of time for SANC00488 in complex with (A) HsCatB, (B) TbCatB, (C) 
TcCatB, (D) TcrCatB and (E) TvCatB cysteine proteases along 13 ns MD simulations. 
 
The obtained Cα atom RMSD values for the HsCatB protease is about 1.6 Å and is relatively 
stable after 1.25 ns (Figure 4.1 A). This indicates that after an initial rise in the RMSD of the 
system it reached equilibrium. The RMSF indicates that areas that fluctuated the most were 
occluding loop region and other loops in the structure (Figure 4.2 A). The Cα atom RMSD of 
TbCatB gradually increased until it reached stability at around 1.25 Å. Compared to HsCatB, the 
occluding loop of TbCatB contains an extra Lys197 residue and the RMSF shows that the area 
with the most fluctuations corresponds to a region that contains this residue.  This is shown by 
the high peak obtained for the RMSF of residues Lys197, Ser 198, Lys 199 and Asn200 of the 
occluding loop area in Figure 4.2 B.  
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The Cα atom RMSD of TcCatB reaches stability around 1.7 Å after 1.25 ns and its RMSF is 
stable. Both the Cα atom RMSD of TcrCatB and TvCatB reached stability at 1.25 Å and 2.00 Å 
respectively. The RMSF of the occluding loop region in TvCatB is the most fluctuating part 
(Figure 4.2 E).  
 
Figure 4.2 showing comparison of Cα atom RMSF (relative to the energy minimized starting 
structure) as a function of time for SANC00488 in complex with (A) HsCatB, (B) TbCatB, (C) 
TcCatB, (D) TcrCatB and (E) TvCatB cysteine proteases along 13 ns MD simulations. 
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Figure 4.3:  Showing comparison of SANC00488 RMSD (relative to the energy minimized 
starting structure) as a function of time when in complex with (A) HsCatB, (B) TbCatB, (C) 
TcCatB, (D) TcrCatB and (E) TvCatB cysteine proteases along 13 ns MD simulations. 
The RMSD of SANC00488 bound to HsCatB can be seen in Figure 4.3 A. the RMSD gradually 
rose until it reached stability at around 2.3 Å after 10 ns. Visual observation of the 
conformational changes during simulation revealed that the ligand was moving further from its 
initial position and further from the active site and interacting residues (Figure 4.4. A-D). At the 
beginning of the simulation, the ligand is interacting with Asn72 and Gl 245 by hydrogen 
bonding. It also forms a hydrophobic interaction with Ala173. π-π-hydrophobic interactions are 
also formed between the ligand and Pro76 and Tyr75 residues. The initial lengths of the bonds 
between the ligand and As 72, Glu245 and Ala173 were 2.53 Å, 3.48 Å, and 3.52 Å respectively 
(Figure 4.4 A). By the end of the simulation, the distances between the residues and the 
corresponding ligand interaction atoms were respectively 20.16 Å, 16.26 Å and 9.32 Å (Figure 
4.5). This suggested that the docking of the ligand in this complex was not a stable arrangement 
at all. 
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Figure 4.4: SANC00488 (Yellow) and interacting HsCatB residues during 13 ns simulations. 
The figures were extracted at (A) 0 ns, (B) 3 ns, (C) 6 ns and (D) 12 ns. The active site Cys 
residue is shown in red and the occluding loop is shown in orange. Distances to the appropriate 
active site residues are shown in green. The ligand is seen to move away from interacting 
residues during simulation. 
 
The RMSD of SANC00488 bound to TbCatB reached equilibrium with RMSD 2.5 Å (Figure 
4.3 B) after about 7.5 ns. Visual inspection of the ligand during 13 ns simulation revealed the 
ligand changing conformation during the simulation (Figure 4.5 A-D). At the beginning of the 
simulation (Figure 4.5 A), the ligand is hydrogen bonded to Phe208 and Ala118. The ligand is 
also bent is such a way that it is able to make hydrophobic interactions with Cys162 and also 
form a hydrogen bond with Asn163. The ligand also has hydrophobic interactions with Ala256 
in the S2 subsite region. After about 3 ns of simulation, the ligand straightens up at the bend, 
placing the corresponding interacting atoms far for interactions with Cys162 and Asn163 
(Figure 4.5 C and D).  In this position, the ligand pushes the occluding loop into a more open 
conformation resulting in a structural change to the protein which in turn contributes to the 
RMSD.   
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Figure 4.5:  SANC00488 (Yellow) and interacting TbCatB residues during 13 ns simulations. 
The Figures were extracted at (A) 0 ns, (B) 3 ns, (C) 6 ns and (D) 12 ns. The active site Cys 
residue is shown in red and the occluding loop is shown in orange. Distances to the appropriate 
active site residues are shown in green. The ligand is seen to move away from interacting 
residues during simulation 
Interactions between SANC00488 and both HsCatB and TbCatB is probably influenced by the 
movement and stability of the occluding loop. The occluding loop of TbCatB has been identified 
by other researchers [23] to have a more stable S1’ opening which could be exploited for 
TbCatB specific inhibitors, while the occluding loop of HsCatB behaves independently from the 
structure and it adapts to changes in the environment [26]. 
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Figure 4.6: 13 ns MD simulation of interactions between SANC0048 and residues (A) Asn72, 
(B) Glu245, (C) Ala73, (D) Pro76, and (E) Tyr 75 in HsCatB. Frames were recorded every 2 ns 
for 13 ns. All the interactions are increasing in length. 
To get more insight into the evolution of the receptor – ligand interactions, bond lengths were 
plotted against frames that were recorded every 2 ns for the simulation time of 13 ns between 
SANC00488 and HsCatB (Figure 4.6) and TbCatB (Figure 4.7). The receptor-ligand 
interactions were determined from the original docked pose using Discovery Studio Visualizer. 
All the intermolecular interactions in the HsCatB-SANC00488 complex gradually increase in 
length until they finally stabilize (Figure 4.6). The distances between the residues and the 
corresponding atoms in the ligand at equilibrium are more than 9Å. To track the π-π interaction 
between the ligand and Pro76 and Tyr75, the distance between the residues and the 
corresponding atoms in the ligand were followed over simulation time. These distances 
increased to more than 10 Å in both cases. This indicates that the interactions were not 
maintained during simulation.  
In Figure 4.7 A, we see the evolution of the hydrogen bond formed between residue Ala118 of 
TbCatB and SANC00488. At the beginning of the simulation the bond is 2.08Å and by the end 
of the simulation it equilibrates at 4.05 Å. 
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Figure 4.7: 13 ns MD simulation of interactions between SANC00488 and residues (A) Ala118, 
(B) Asn163, (C) Phe208, (D) Cys162, (E) Gly328, and (F) Ala256 in TbCatB. Frames were 
recorded every 2 ns for 13 ns.  
The hydrogen bond between Cys162 and the hydrophobic interactions between Asn163 were 
not maintained during simulation (Figure 4.7 B and D). 
The hydrogen bond (as determined by DS), length between Phe182 and the compound is 
observed fluctuating between a maximum length of about 5.6 Å and a minimum length of 2.2 Å 
through the simulation (Figure 4.7 C) and (Figure 4.8). This bond length interaction was at a 
minimum during the conformational change (Figure 4.8 C) that the ligand went through. This 
suggests that this interaction is important for this complex formation. At the beginning of the 
simulation, the hydrogen atom of the compound that interacts with the oxygen atom of the 
Phe208 residue is facing towards the residue (Figure 4.8 A). In this position the distance 
between the two interacting atoms is low (Figure 4.8 A, C, E, and G). During simulation, 
repositioning of the compound resulted in the hydrogen atom facing away from the Phe208 
oxygen, thereby increasing the distance (Figure 4.8 B, D and F). However, the interaction 
distance is at its minimum for longer durations during the simulation than when it is at its 
maximum. 
The hydrophobic interactions distance between the ligand and Ala256 changed from 4.07 Å to 
4.41 Å. The distance between the Gly328 residue and the ligand interacting atom was originally 
5.13 Å and so there was no hydrogen bond depicted by DS initially. After simulation the 
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distance between the two molecules became 2.31 Å. Since the Gly328 is in the S2 subsite that 
determines specificity of this protease, it is likely that a hydrogen bond was formed during 
simulation.  
 
Figure 4.8: 13 ns MD simulation of interactions between SANC00488 and residues Phe 208.  
(A) - (G) shows the orientation of interacting atoms at different times during the simulation. 
Phe208 is located in the occluding loop (orange). 
4.6. Conclusion 
Molecular dynamics simulations of SANC00488 in complex with cathepsin B proteases from 
human and Trypanosomal spp. was done to obtain the complex structures that resemble 
physiological conditions and to predict the binding mode of the compound into the structures. 
The results demonstrated that the compound forms stable complexes with Trypanosomal spp. 
cathepsin B proteases and not with human cathepsin B protease. Conformational changes of the 
ligand and interacting residues during simulation was observed for TbCatB and HsCatB 
complexes,  which may be expected during dynamics and there are other studies that highlight 
that changes in the docked poses of ligands may be expected during simulation [114]. The 
position and orientation of the ligand changed during simulation (Figure 4.4. A-D and Figure 
4.5. A-D). This demonstrates the importance of MD simulation after docking  [115] to 
determine the correct binding mode of compounds. Residues that are important for 
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SANC00488-TbCatB complex formation are Gly328 of the S2 subsite, Phe208, and the Ala256. 
MD simulation of SANC00488 in complex with TcCatB, TcrCatB and TvCatB demonstrated 
that the complexes are stable. The compound however does not form a stable complex with 
HsCatB. 
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Chapter 5.   
5.1.  Conclusion and Future Prospects 
Using PDB ID: 4HWY sequence of TbCatB, a total of four Trypanosomal and one human 
cathepsin B protease homolog sequences were retrieved (Table 2.0). Comparative analysis was 
carried out using multiple sequence analysis (MSA) (Figure 2.1) and phylogenetic analysis 
(Figure 2.4). MSA showed that although there are highly conserved residues, like at the active 
site, there are regions, in the occluding loop and at the S2 subsite, where the sequences differ 
significantly. Conservation of residues at the active site is consistent with characteristics of C1 
cysteine proteases [12], [117]. The occluding loop of TbCatB has three extra residues, Lys197, 
Try202 and Phe208 residues which are not available in the HsCatB protease. The occluding loop 
of TbCatB also contains a “FNFD” motif which corresponds to “GEGD” motif in HsCatB. The 
“FNFD” motif in TbCatB results in a more stable occluding loop and consequently a more 
stable S1’ opening while the “GEGD” in HsCatB results in a more flexible occluding loop at 
that region [23]. Another major difference is in the S2 subsite where TbCatB has Gly328 residue 
while HsCatB has Glu245 residue in the corresponding position. Phylogenetic analysis results 
showed a clustering of all the Trypanosomal spp. cathepsin B proteases with the HsCatB 
forming an outgroup. 
High quality homology models were calculated for T.congolense, T.cruzi and T.vivax cathepsin 
B proteases using MODELLLERv9.10. From structural comparison of the homolog proteins, 
fold conservation was maintained in the proteases at the active. At the S2 subsite region, there is 
a difference in the depth of the pocket (Figure 2.2). 
High throughput screening of 600 SANCDB resulted in nine compounds,  SANC00 478, 479, 
480, 481, 482, 488, 489, 490 and 491, having a strong affinity for Trypanosoma spp. cathepsin 
B proteases than HsCatB. SANC00488 has the strongest binding to the Trypanosoma spp. 
cathepsin B proteases and the weakest binding to HsCatB protease. This is shown by the 
docking energy of this compound (Fgure 3.14), and a preference for binding along the active site 
in Trypanosoma spp. cathepsin B proteases. 
Molecular dynamics (MD) simulations show that the complexes between SANC00488 and 
TbCatB, TcCatB, TcrCatB and TvCatB are stable and do not dissociate during simulation. The 
complex between this compound and HsCatB however is unstable and comes apart during 
simulation (Figure 4.4). The complex between TbCatB and SANC00488 (Figure 4.5) shows the 
compound finding a more favourable position in the active site of this protease and thereby 
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forming a more stable complex. From this complex, residues that are important for interaction 
are Gly328 of the S2 subsite, Phe208, and Ala256.  
 
Further insights on the effect of binding residue variations between HsCatB and TbCatB could 
be determined through MD simulations of SANC00 478, 479, 480, 481, 482, 489, 490 and 491 
to determine the effect of simulation on these complexes and the residues that are involved 
during interaction for each of them. These simulations were not done due to time restraints. 
Calculations of binding free energies would have contributed to determine energies contributed 
by van der Waals forces, electrostatic energy, polar and non-polar solvation energy and 
contributed to determine key interactions involved in ligand binding. Binding free energy 
calculations were also not done due to time constraints. 
In addition to performing MD simulations of the remaining lead compounds and calculating the 
binding free energy, the lead compounds could be analysed in the laboratory to determine their 
effect in vivo and in vitro. The toxicity of each compound would also have to be determined 
experimentally. 
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Appendix 1A 
 
 
Appendix 1A-1: PIR aligment used for calculation of T. congolense model from using HsCatB 
crystal structure (PDB ID 3CBJ) as a template. 
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Appendix 1A-2: PIR aligment used for calculation of T. congolense model from using 
Trypanosoma cathepsin B crystal structure (PDB ID 3HHI) as a template. 
 
 
Appendix 1A-3: PIR aligment used for calculation of T. congolense model from using HsCatB 
crystal structure (PDB ID 3CBJ) and Trypanosoma cathepsin B crystal structure (PDB ID 
3HHI) as a templates. 
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Appendix 1A-4: PIR aligment used for calculation of T. cruzi model from HsCatB crystal 
structure (PDB ID 3CBJ) as a template. 
 
Appendix 1A-5: PIR aligment used for calculation of T.cruzi model from using Trypanosoma 
cathepsin B crystal structure (PDB ID 3HHI) as a template. 
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Appendix 1A-6: PIR aligment used for calculation of T. cruzi model from using HsCatB crystal 
structure (PDB ID 3CBJ) and Trypanosoma cathepsin B crystal structure (PDB ID 3HHI) as a 
templates. 
 
Appendix 1A-7: PIR aligment used for calculation of T. vivax model from using HsCatB crystal 
structure (PDB ID 3CBJ) as a template. 
 
 
Appendix 1A-8: PIR aligment used for calculation of T.vivax model from using Trypanosoma 
cathepsin B crystal structure (PDB ID 3HHI) as a template. 
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Appendix 1A-9: PIR aligment used for calculation of T. vivax model from using HsCatB crystal 
structure (PDB ID 3CBJ) and Trypanosoma cathepsin B crystal structure (PDB ID 3HHI) as a 
templates. 
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Appendix 2A 
 
Appendix 2A: Phylogenetic analyses of TbCatB homologs. The tree shows distinct clustering 
of trypanosomatidae family homologs from the HsCatB protease homolog. The MSA was made 
using PROMALS3D. 
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Appendix 3A 
 
 
Appendix 3A-1: SANC00 (A) 478, (B) 479, (C) 480, (D) 481, (E) 482 two dimentional 
representations. All these compounds are cephalostatins with Anticancer activity. 
 
 
Appendix 3A-2: SANC00 (A) 488, (B) 489, (C) 490, (D) 481, (E) 491 two dimentional 
representations. All these compounds are cephalostatins with Anticancer activity. 
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#!/usr/bin/python 
#this script prepares ligands for docking (remove) 
import os 
from os import listdir 
 
ligandarray = listdir("ligands")#tells it to look in the ligand directory 
 
for ligand in ligandarray: 
print ligand 
if '.pdb' in ligand: 
os.system("prepare_ligand4.py -l ligands/" + ligand) #adds a path to the 
ligands folder 
 
Appendix 3A-1 The script that was used for preparing ligand pdbqt files for docking 
 
#!/usr/bin/python 
#this script prepares a protein for docking (remove) 
import os 
from os import listdir 
 
proteinarray = listdir("proteins")#tells it to look in the proteins directory 
 
for protein in proteinarray: 
print protein 
os.system("prepare_receptor4.py -r proteins/" + protein) #adds a path to the 
proteins folder 
 
Appendix 3A-2 The script that was used for preparing protein pdbqt files for docking 
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#!/usr/local//bin/python 
 
import os  
from os import listdir 
#to list all the files we need for vina 
 
protein_array = listdir("/home/gaone/SANCDB_DOCKINGS/1GMY/proteins_pdbqt/") 
ligand_array = listdir("/home/gaone/SANCDB_DOCKINGS/ligands_pdbqt") 
 
for protein in protein_array: 
for ligand in ligand_array: 
prot=protein[:-6] 
lig=ligand[:-13] 
 
#vina_file=lig+"_"+prot+".vina"; 
vina_file="/home/gaone/SANCDB_DOCKINGS/1GMY/vina/" + prot + "_" + lig + 
".vina" 
print "name is " + vina_file 
 
vinafile=open(vina_file,'w') 
 
vinafile.write("receptor = /home/gaone/SANCDB_DOCKINGS/1GMY/proteins_pdbqt/" 
+ protein +"\n") 
vinafile.write("ligand =   /home/gaone/SANCDB_DOCKINGS/ligands_pdbqt/" + 
ligand +"\n") 
 
vinafile.write("out =      /home/gaone/SANCDB_DOCKINGS/1GMY/vina_out/" + 
protein[:-6] +"_" + ligand[:-13] + ".all.pdbqt\n") 
vinafile.write("log=       /home/gaone/SANCDB_DOCKINGS/1GMY/vina_log/" + 
protein[:-6] + "_" + ligand[:-13] + ".log\n") 
 
vinafile.write("center_x = -16.67\n") 
vinafile.write("center_y = -17.76\n") 
vinafile.write("center_z = 17.76\n") 
 
vinafile.write("size_x = 30.000\n") 
vinafile.write("size_y = 31.875\n") 
vinafile.write("size_z = 31.875\n") 
 
vinafile.write("energy_range = 4\n") 
vinafile.write("exhaustiveness = 4\n") 
vinafile.write("cpu = 4\n") 
 
vinafile.close() 
 
vinafile.close() 
 
 
Appendix 3A-3: The scripts that was used for writing Vina configuration files 
for docking validation and for HTS. 
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#!/usr/bin/python 
#this script extracts docking energies from vina output all.pdbqt file 
(remove) 
import os 
from os import listdir 
 
dockingarray = listdir("vina_out")#tells it to look in the proteins directory 
 
for docking in dockingarray: 
#print docking 
outputstream = os.popen("head -n2 vina_out/"+docking) 
firstline=outputstream.readline(); 
secondline=outputstream.readline(); 
energy=secondline[24:34] 
#print docking + ":" + energy; 
print(docking + ":" + energy  ) 
#print ""+txt_file_name+" is created" 
#print docking_energy_file 
#os.system("prepare_receptor4.py -r proteins/" + protein) #adds a path to the 
proteins folder 
 
 
Appendix 3A-4: The scripts that was used extracting lowest docking energy poses from vina 
output all.pdbqt file. 
 
 
 
Appendix 3A-5: Showing docking energies of SANC00488  in TbCatB, TcCatB, TcrCatB, 
TvCatBa and HsCatB. The compound binds more strongly to trypanosomal spp. cathepsin B 
proteases than to human cathepsin B protease. 
 
